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The growth hormone secretagogue receptor type 1a (GHSR1a) critically 
regulates the central and peripheral actions of ghrelin as a growth 
hormone (GH) secretagogue, an orexigenic peptide, and a long-term 
regulator of energy homeostasis. GHSR1a classically exerts its 
intracellular effects through G-protein activation, mainly via Gq/11 and 
Gi/o. However, recent evidence has demonstrated that β-arrestins act as 
molecular mediators of G-protein independent signaling by acting to 
scaffold of a variety of signaling proteins. Thus, it is becoming increasingly 
evident that β-arrestins, originally discovered as mere adaptor proteins for 
the GHSR1a endocytosis, have much broader signaling and physiological 
roles. What is not clear however is whose factors regulate GHSR1a coupling 
to β-arrestin-dependent signaling and the processes that regulate the 
relative contribution of G-protein versus β-arrestin-dependent signaling. It is 
now well established that GPCR phosphorylation plays a crucial role in the 
recruitment and activation of β-arrestin-dependent signaling. Indeed, recent 
studies have gone further and suggested that the phosphorylation pattern of 
a GPCR constitutes a barcode that determines, at least in part, the signaling 
outcomes. Thus, the main aim of this study was to determine the possibility 
that GHSR1a regulates β-arrestin-dependent signaling in a phosphorylation 
dependent manner and, thus, to establish the existence of a phosphorylation 
barcode that impacts on GHSR1a signaling. This global aim is divided into the 
following particular goals: 
1. To determine the phosphorylation sites in the C terminus of the 
GHSR1a.  
2. To analyze the impact that GHSR1a phosphorylation on various 
signaling and cellular responses. 




4. To determine the key structural elements of ghrelin which ensure its 
bioactivity in order to identify the minimum region of amino acids 































1.0 GROWTH HORMONE SECRETAGOGUE RECEPTOR (GHSR) 
1.1 GHSR Gene 
 The human GHSR (hGHSR) is a single highly conserved gene located 
on chromosome 3q26.2 of approximately 4.3 kb. hGHSR gene is composed of 
two exons separated by one intron, whose alternative splicing generates two 
types of mRNA: GHSR1a and GHSR1b1. GHSR type 1a is encoded by both 
exons after splicing elimination at position 796/797 from the start codon, of 
2152 nucleotides belonging to the intron sequence of the pre-mRNA. As a 
consequence, human GHSR1a is a 366-amino acid G protein-coupled 
receptor (GPCR) with seven transmembrane regions whose molecular mass 
is approximately 41 kDa. While exon 1 is composed of the 5’-untranslated 
region and the first 265 amino acids encoding for the transmembrane (TM) 
domains 1–5, exon 2 encodes the 101 amino acids of TM domains 6 and 7 
and includes the 3’-untranslated region. On the other hand, GHSR type 1b is 
encoded by the exon 1 and retains the first 74 nucleotides of the GHSR1a 
intronic sequence, which generates a GPCR isoform of 289 amino acids 
containing only the first five transmembrane regions and 24 dissimilar amino 
acids at the C-terminal region comparing with the GHSR1a sequence, due to 
the use of an alternative stop codon2,3 (Figure 1).  
                                                                
1 McKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS, Smith RG, Van 
der Ploeg LH, Howard AD. Molecular analysis of rat pituitary and hypothalamic 
growth hormone secretagogue receptors. Mol Endocrinol 1997; 11: 415–423. 
2 Petersenn S, Rasch AC, Penshorn M, Beil FU, Schulte HM. Genomic structure and 
transcriptional regulation of the human growth hormone secretagogue receptor. 
Endocrinology 2001; 142: 2649–2659. 
3 Camiña JP. Cell Biology of the Ghrelin Receptor. Journal of Neuroendocrinology, 




Figure 1. Alternative splicing of GHSR gene. An alternative splicing of GHSR 
gene generates GHSR1a and GHSR1b. Generation of the 5TM domains 
truncated ghrelin receptor results from failure to remove the intron between 
the two coding exons and the use of an alternative stop codon and a 
polyadenylation signal within the intron (dark box) (Extracted from J Mol 
Signal. 2012 Sep 1;7(1):13). 
 
 The expression of each GHSR subtype has been demonstrated to be 
different. While to GHSR1a mRNA is predominantly expressed in the pituitary 
and the hypothalamus, the GHSR1b mRNA is widespread in tissues as varied 
as liver, pancreas, breast, pituitary, myocardium, skin, thyroids or colon4. In 
addition, location studies have been shown that GHSR1a tagged with green 
fluorescent protein (GFP) was localized in the plasma membrane of HEK293 
cells, whereas GHSR1b tagged with the same flag was confined to the 
nucleus. Moreover, GHSR1a homodimers were founded in all subcellular 
                                                                
4 Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, 
Carpenter R, Grossman AB, Korbonits M. The tissue distribution of the mRNA of 




fractions while GHSR1a/GHSR1b heterodimers were concentrated in the 
endoplasmic reticulum5,6. 
 In terms of activation and associated functionality, massive 
differences have also been determined for both types. Contrary to GHSR1b 
receptor which fails to bind ghrelin, the type 1a has shown high affinity for 
the family of synthetic growth hormone (GH) secretagogues and specific 
binding to S3 acylated ghrelin. Indeed, this S3 acylation confers to ghrelin the 
high conformational flexibility necessary for the interaction with GHSR1a. In 
fact, ghrelin peptide functionality was reduced by experimental acylation of 
other S residues (S2, 6, and 18)7. The GHSR1a high binding affinity to acylated 
ghrelin is related with the modulation of a multiplicity of physiological 
functions such as energy homeostasis, GH secretion, food intake, adiposity, 
glucose metabolism, improvement of cardiovascular functions, modulation 
of stress and anxiety, protection against muscle atrophy or body weight 
gain8,9. On the contrary, the functional activity of GHSR1b remains to be 
                                                                
5 Smith RG, Jiang H, Sun Y. Developments in ghrelin biology and potential clinical 
relevance. Trends Endocrinol Metab. 2005;16(9):436-42. 
6 Chow KB, Sun J, Chu KM, Tai Cheung W, Cheng CH, Wise H. The truncated ghrelin 
receptor polypeptide (GHS-R1b) is localized in the endoplasmic reticulum where it 
forms heterodimers with ghrelin receptors (GHS-R1a) to attenuate their cell surface 
expression. Mol Cell Endocrinol. 2012 Jan 2;348(1):247-54. 
7 Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV, Warren VA, 
Howard AD, Van Der Ploeg LH, Heck JV.Minimal Sequence of Ghrelin Necessary for 
Activation of Growth Hormone Secretagogue Receptor 1a Journal of Medicinal 
Chemistry 2000 43 (23), 4370-4376.  
8 Sivertsen B, Holliday N, Madsen AN, Holst B. Functionally biased signalling 
properties of 7TM receptors - opportunities for drug development for the ghrelin 
receptor. Br J Pharmacol. 2013 Dec; 170(7):1349-62. 
9 Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, 
Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, D'Alessio D, Depoortere 
I, Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S, Dickson 
SL, Diéguez C, Granata R, Grill HJ, Grove K, Habegger KM, Heppner K, Heiman ML, 
Holsen L, Holst B, Inui A, Jansson JO, Kirchner H, Korbonits M, Laferrère B, LeRoux 
CW, Lopez M, Morin S, Nakazato M, Nass R, Perez-Tilve D, Pfluger PT, Schwartz TW, 
Seeley RJ, Sleeman M, Sun Y, Sussel L, Tong J, Thorner MO, van der Lely AJ, van der 
Ploeg LH, Zigman JM, Kojima M, Kangawa K, Smith RG, Horvath T, Tschöp MH. 
Ghrelin. Mol Metab. 2015 21;4(6):437-60. 
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unclear. Curiously, the concurrent expression of GHSR1b and GHSR1a 
attenuates the signal transduction capacity of GHSR1a, suggesting that both 
receptors may be interacting. Besides, further heterodimerization studies 
have also demonstrated that GHSR1b exerts a dominant negative inhibition 
of GHSR1a signaling10,11.  
 The study of the promoter region of hGSR gen has shown a tissue-
specific regulation. Sequencing analysis determined that the major 
transcription start site is an adenosine residue located 227 nucleotides 
upstream from the ATG translation initiation codon, as well as, it determines 
that the 5′-flanking region does not contain the usually required promoter 
regions, such as a TATA box, CAAT box or GC-rich region. Nonetheless, the 
sequencing study also revealed initiator elements located at -215 and -237 
surrounding the transcription start site. In addition to the initiation elements 
in the 5′-flanking region of the hGHSR gen have also been identified a 
number of binding transcription factors among which should be highlighted 
the PUO-domain factors, Ptx1, Ptx2, Oct-1, Brn-2 and Pit-1 for their 
implication in the pituitary-specific expression of the gen. Furthermore, 
transient transfections of the hGHSR gene promoter shown significant 
activity in GH4 and GH3 cells (somatotroph pituitary cell lines), whereas no 
activity was detected in other tissues cell lines such as COS-7 (monkey kidney 
cells), Skut-1B (human endometrium cells), LHRH (mouse hypothalamic cells), 
GT1-7 (neuronal cells), AtT20 (mouse corticotroph pituitary cells), HeLa 
(human epithelioid cervix carcinoma cells) or EP1 (neuroblastoma cells) 
corroborating the tissue-specifity. The sequenced work also revealed the 
                                                                
10 Chan CB and Cheng CH. Identification and functional characterization of two 
alternatively spliced growth hormone secretagogue receptor transcripts from the 
pituitary of black seabream Acanthopagrus schlegeli.  Mol Cell Endocrinol.  2004 Feb 
12;214(1-2):81-95. 
11 Mary S, Fehrentz JA, Damian M, Gaibelet G, Orcel H, Verdié P, Mouillac B, Martinez 
J, Marie J, Banères JL. Heterodimerization with Its splice variant blocks the ghrelin 
receptor 1a in a non-signaling conformation: a study with a purified heterodimer 
assembled into lipid discs. J Biol Chem. 2013 Aug 23;288(34):24656-65. 
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presence of putative binding sites for activator proteins 1 and 2, basic helix-
loop-helix factors, PEA-3, Myb and NF-IL6, some of which regulate the basal 
activity of the gene promoter. In addition, several systems suggest that 
hGHSR gen could be under regulatory control and the study of the hormonal 
regulation of the 5′-flanking region demonstrate on the one hand the 
stimulatory effect of the thyroid hormone and estrogen and on the other 
hand, the inhibitory effect of glucocorticoids in the promoter activity through 
the transcriptional mechanism involving nuclear factors2,12,13. However, to 
determine the specific transcription factors which regulate the promoter 
activity of the hGHSR gene, further studies need to be done. 
 The sequence of the hGHSR gen and the elucidation of its location 
and structure have been demonstrated to be crucial in the identification of 
mutations that could lead to better understanding of several diseases and 
even defining the GHSR gene as a possible epigenetic marker. It has been 
shown that a single nucleotide polymorphism (SNPs) and haplotypes within 
the hGHSR gene region might influence susceptibility to obesity and be 
involved on its pathogenesis due an increment on food intake14, although 
exist other studies that have not been able to relate SNPs with obesity, 
weight regulation, food intake or GH secretion making these point 
controversial15,16. On the other hand, a link between epigenetic down-
                                                                
12 Kaji H, Tai S, Okimura Y, Iguchi G, Takahashi Y, Abe H, Chihara K. Cloning and 
characterization of the 5’-flanking region of the human growth hormone 
secretagogue receptor gene. J Biol Chem 1998; 273: 33885–33888. 
13 Kaji H, Kishimoto M, Kirimura T, Iguchi G, Murata M, Yoshioka S, Iida K, Okimura Y, 
Yoshimoto Y, Chihara K. Hormonal regulation of the human ghrelin receptor gene 
transcription. Biochem Biophys Res Commun 2001; 284: 660–666. 
14 Baessler A, Hasinoff MJ, Fischer M, Reinhard W, Sonnenberg GE, Olivier M, 
Erdmann J, Schunkert H, Doering A, Jacob HJ, Comuzzie AG, Kissebah AH,Kwitek AE. 
Genetic linkage and association of the growth hormone secretagogue receptor 
(ghrelin receptor) gene in human obesity. Diabetes. 2005 Jan;54(1):259-67. 
15 Hess O, Admoni O, Khayat M, Elias G, Almagor T, Shalev SA, Tenenbaum-Rakover Y. 
Ghrelin and growth hormone secretagogue receptor (GHSR) genes are not commonly 
involved in growth or weight abnormalities in an Israeli pediatric population. J Pediatr 
Endocrinol Metab. 2012;25(5-6):537-40. 
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regulation of hGHSR gen by DNA hypermethylation and breast cancer cell 
invasion has been reported17,18 , as well as, has been describe that GHSR 
hypermethylation may have a functional role in tumorigenesis of other 
cancers. Bisulfite pyrosequencing studies has shown substantial 
hypermethylation at the promoter and first exon of the GHSR gen revealing 
GHSR hypermethylation as a common epigenetic mark that distinguishes 
cancers from non-cancer specimens regardless of tumor type. For this 
reason, GHSR methylation could be used as a signature with high specificity 
and sensitivity of cancer detection19. Moreover, common variants founded in 
the hGHSR region are associated with parameters of left ventricular mass 
and geometry independent of blood pressure and body mass in the general 
population and, thus, may be involved in the pathogenesis of left ventricular 
hypertrophy20. However, the results of all of these studies suggest that the 
effects of genetic variants in GHSR gen are modest, making necessary further 
studies of this gen in larger population groups with more individual diversity 
to investigate its direct effect on diseases. 
                                                                                                                                           
16 Luglio HF, Inggriyani CG, Huriyati E, Julia M, Susilowati R.Association of SNPs in 
GHSR rs292216 and rs509035 on dietary intake in Indonesian obese female 
adolescents. Int J Mol Epidemiol Genet. 2014 Dec 15;5(4):195-9. 
17 Botla SK, Gholami AM, Malekpour M, Moskalev EA, Fallah M, Jandaghi P, Aghajani 
A, Bondar IS, Omranipour R, Malekpour F, Mohajeri A, Babadi AJ, Sahin Ö, Bubnov VV, 
Najmabadi H, Hoheisel JD, Riazalhosseini Y.Diagnostic values of GHSR DNA 
methylation pattern in breast cancer. Breast Cancer Res Treat.2012 Oct;135(3):705-
13. 
18 Pabalan NA, Seim I, Jarjanazi H, Chopin LK. Associations between ghrelin and 
ghrelin receptor polymorphisms and cancer in Caucasian populations: a meta-
analysis.BMC Genet.2014Nov 7;15:118. 
19 Moskalev EA, Jandaghi P, Fallah M, Manoochehri M, Botla SK, Kolychev OV, Nikitin 
EA, Bubnov VV, von Knebel Doeberitz M, Strobel O, Hackert T, Büchler MW, Giese N, 
Bauer A, Muley T, Warth A, Schirmacher P, Haller F, Hoheisel JD, Riazalhosseini Y. 
GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic 
value in a broad spectrum of cancers. Oncotarget. 2015 28;6(6):4418-27. 
20 Baessler A, Kwitek AE, Fischer M, Koehler M, Reinhard W, Erdmann J, Riegger G, 
Doering A, Schunkert H, Hengstenberg C. Association of the Ghrelin receptor gene 
region with left ventricular hypertrophy in the general population: results of the 




1.2. GHSR protein 
 The ghrelin receptor GHSR1a is a typical G protein-coupled receptor 
(GPCR) which belongs to a family of receptors with its own name. The ghrelin 
receptor family is a group of GPCRs type A which includes motilin receptor 
(~52% homology), neurotensin receptors 1 and 2 (~35% homology), GPR39 
(~30% homology) and neuromedin receptors 1 and 2 (~30% homology)1,21,22 




Figure 2. The ghrelin receptor family. Schematic phylogenic tree of the 
ghrelin receptor family indicating the relative relationship of the receptor 
(Modified from J Biol Chem. 2004 Dec 17;279(51):53806-17). 
 
The receptors of this family are 7TM domains receptors which are localized 
in the plasma membrane and responsible for translating extracellular signals 
into intracellular responses. The critical role of 7TM receptors regulating 
several physiological processes makes them the targets of 30% of the drugs 
                                                                
21 McKee KK, Tan CP, Palyha OC, Liu J, Feighner SD, Hreniuk DL, Smith RG, Howard AD, 
Van der Ploeg LH. Cloning and characterization of two human G protein-coupled 
receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and 
neurotensin receptors. Genomics. 1997 Dec 15;46(3):426-34. 
22 Smith RG, Leonard R, Bailey AR, Palyha O, Feighner S, Tan C, Mckee KK, Pong SS, 
Griffin P, Howard A. Growth hormone secretagogue receptor family members and 










currently on the market23. 7TM receptors are called so because they share a 
seven α-helix hydrophobic transmembrane domains structure which includes 
three intra- and extracellular loops, an N-terminal domain located on the 
extracellular side and a carboxy terminus on the intracellular side. Docking 
studies has shown that in the case of GHSR1a, the TM domains forms a 
round calyx-like structure with the transmembrane helices organized in an 
anticlockwise sense and the Pro residues in the center. In this organization, 
the third domain takes the most central position in transmembrane segment 
and the fifth occupy the most peripheral one. At the same time, domains 2, 3 
and 7 forms the core of the transmembrane structure while domains 1 and 5 
are in the external positions. The three extracellular loops mainly stabilized 
by polar contacts adopt hairpin geometries. The hairpin structure is also 
adopted by the N-terminal domain which involves residues between M1 and 
D32 and it is stabilized by hydrogenous bonds and electrostatic interaction 
between the D32 and the ammonium group that close the hairpin. Lastly, the 
docking studies shown the C-terminal tail as a helix–turn–helix structure with 
an eighth helix between S327and P342 perpendicular to seven helix and rich 
in residues like K328, K329, R331, and R336 which are positively charged and 
anchor the terminal domain to phospholipidic heads24,25.  
 
 
                                                                
23 Kenakin, T. and Christopoulos, A. Signalling bias in new drug discovery: detection, 
quantification and therapeutic impact. Nat. Rev. Drug Discov. 2013; 12, 205–216 
24 Pedretti A, Villa M, Pallavicini M, Valoti E, Vistoli G. Construction of human ghrelin 
receptor (hGHS-R1a) model using a fragmental prediction approach and validation 
through docking analysis. J Med Chem. 2006 Jun 1;49(11):3077-85. 
25 Pedretti A, Vistoli G.Modeling of human ghrelin receptor(hGHS-R1a) in its close 




Conformational changes of GHSR1a activation and basal activity 
 Since GHSR1a was discovered, the conformational changes 
associated to its activation have been studied using a number of biochemical 
and biophysical approaches. Docking and mutational studies was 
performance with the purpose of elucidate the physiological impact of these 
alterations as well as the pharmacological consequences of the 
corresponding mutations. Among the functional alterations discovered it was 
found shifts in basal signaling, differences in the response to ghrelin and 
other agonists, distinct inverse agonist function and variations in the level of 
receptor expression. Key residues for ghrelin binding are located on the 
opposing inner faces of the TM domains 3, 6 and 7 which is in line with the 
toggle-switch model described for the 7TM receptors activation. According 
to this model, when the receptor is activated by its agonist, TM domains 6 
and 7 vertical fluctuate around a pivot corresponding to the conserved P 
amino acid in the middle of each of these helices. The extracellular region of 
TM domains 6 and 7 helices seems to move inward toward the third TM 
domain while the intracellular ends move in the opposite direction making 
accessible the epitopes recognized for instance by G proteins. It has been 
proposed additional contact points for ghrelin and the receptor located for 
example in the loop regions but E09 of TM domain 3 seems to be the major 
hit for ghrelin26,27,28. The interaction of other GHSR1a natural or synthetic 
agonist was also studied. These works reflect that all the agonist shown a 
high dependence of E124 in the third TM domain as well as ghrelin. 
However, it is remarkable the fact that they all were affected by mutation of 
                                                                
26 Holst B, Schwartz TW. Ghrelin receptor mutations--too little height and too much 
hunger. J Clin Invest. 2006 Mar;116(3):637-41. 
27 Holst B, Lang M, Brandt E, Bach A, Howard A, Frimurer TM, Beck-Sickinger A, 
Schwartz TW.Ghrelin receptor inverse agonists: identification of an active peptide 
core and its interaction epitopes on thereceptor.Mol Pharmacol.2006Sep;70(3):936-
46 
28 Schwartz TW,  Frimurer TM,  Holst B,  Rosenkilde MM,  Elling CE.  Molecular 
mechanism of 7TM receptor activation - a global toggle switch model. Annu Rev 
Pharmacol Toxicol. 2006;46:481-519. 
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D99 in the second TM domain, while ghrelin was not affected by this 
mutation. Although the ligands have shown different binding sites to the 
receptor, they share a common binding pocket with the endogenous agonist 
on the opposing faces of TM domains 3, 6 and 7 of the ghrelin receptor. 
Some of the agonists studied also demonstrate to be ago-allosteric 
modulators, i.e. peptides that modulate dose-response curve for ghrelin in 
terms of potency and efficacy. Mutational map for allosteric properties of 
these peptides overlaps with its agonism map but allosteric effect is different 
and includes fewer residues in the main ligand binding pocket29 (Figure 3).  
 Worthy of note, it is the fact that the GHSR1a receptor apparently 
shows a high constitutive activity due to its ability to interchange active and 
inactive conformations itself. This ligand independent activity seems to be 
control by an aromatic cluster located in the ghrelin binding pocket form by 
F279 in the TM6, and F309 and F312 in the TM domain 7 which are capable 
of stabilize the active conformation of the receptor without any ligand 
present30,31. It was also describe the importance of W276 (TM domain 3) and 
V131 and I134 (TM domain 6) in the maintenance of the basal activity, but 
more interesting is the fact that the second extracellular loop was also 
reported to be crucial for the basal activity of the receptor despite being far 
from the ghrelin binding pocket. The constriction of the α-helix structure of 
the second loop affects the free movement of TM domain 5 relative to the 
third TM domain which is required to establish the aromatic interactions. 
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Especially important to maintain the α-helix structure is the aliphatic A204 
whose mutation reduces dramatically the basal activity of the receptor 
keeping the capacity for ghrelin binding. The mutation of this A204 has also 
shown a reduction in the surface receptor expression and it was described in 
patients who suffer from obesity and short stature (Figure 3)32,33,34,35,36.  
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Figure 3. Key sites for agonist activation and constitutive activity of 
GHSR1a. The picture represents the external surface of the receptor, with 
TMs indicated by 1–7. The binding surfaces for ghrelin are in dark blue and 
the sites involve in others agonist interactions in light blue. The red area 
represents the pocket bordered by aromatic amino acids that determines 
constitutive activity. The crucial interaction for constitutive activity between 
ECL2 and TM3 is also represented (Extracted from Pharmacol Rev. 2014 
Oct;66(4):984-1001). 
 
Thus, blocking the basal activity of the GHSR1a by means agonists and/or 
antagonists could be a challenge point for effective treatment of obesity. 
Contrary to the agonists, the inverse agonist peptides bind in an extended 
pocket which involves D99, the last amino acid of the second TM domain and 
TM domains 3, 4, 5, 6 and 7. It is proposed that the inverse agonists prevent 
the spontaneous receptor activation by inserting relatively deeply across the 
main ligand-binding pocket and sterically blocking the movement of TM 
domains 6 and 7 into active conformation interacting with the aromatic 
cluster essential for ghrelin action (F279, F309 and F312). Unlike agonists, the 
invert agonist does not shown dependence of E124 of TM domain 3, but all 
the inverse agonists share a high dependence of the D99. It is noteworthy 
that minor changes in the peptides sequence determine between agonism 
and antagonism. Furthermore, the S123 of the receptor could be tricky for 




2.1 From gene to peptide 
 Ghrelin is a peptide hormone originally isolated from rat stomach by 
reverse pharmacology and identified as the endogenous ligand for GHSR1a. 
The name indicates its ability to stimulate GH release because “ghre” is a 
word root for “grow” in Proto-Indo-European languages37.  
The human ghrelin/obestatin prepropeptide gene (GHRL) is located on the 
short arm of chromosome 3 in the position 3q 25-26. The first studies of the 
ghrelin gene describe four exons and another short exon of 20 base pairs, 
which encodes part of the 5’-untranslated region and is transcribed as a 
minor component of ghrelin mRNA38,39. However, more recent studies have 
revealed the existence of a number of alternative upstream exons in the 
ghrelin gene (exon -1, exon 0, and extended exon 1), increasing the 
complexity of this gene40 (Figure 4).  The 5’-flanking region of the human 
GHRL gene contains a TATA box-like sequence (TATATAA), but is not able to 
affect the promoter activity, suggesting that this element is not used. 
Moreover neither a typical GC nor a CAAT box was found in the promoter 
region. However, different activating sequences was describe in TT cells, a 
human medullary carcinoma cell line, and ECC10 cells, a human stomach-
derived cell line, suggesting that ghrelin gene expression may be cell-type 
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specific39,41,42. The 5’-flanking region of the human GHRL gene has also 
exhibit several E-box consensus sequences and  putative binding sites for 
several transcription factors, such as AP2, basic helix-loop-helix (bHLH), PEA-
3, Myb, NF-IL6, hepatocyte nuclear factor-5, and nuclear factor-ĸβ(NF-ĸβ), as 
well as, half-sites for estrogen and glucocorticoid response elements38,39,41. 
Ablation or site-directed mutagenesis of E-box consensus sequences 
decreased the promoter activity in TT cells, implicating them in promoter 
activation. Upstream stimulatory factors (USF), a member of the bHLH family 
of transcription factors, bind to these E-box elements and may thus regulate 
human ghrelin gene expression. Other report also indicates that KLF4 
(Krüppel-like factor 4) positively regulates human ghrelin gene expression by 
binding to a KLF-responsive element39,43. 
 As its own name indicates ghrelin/obestatin prepropeptide gen, in 
addition to ghrelin, also encodes the 23 amino acid peptide obestatin as well 
as small signal peptides. The 28 amino acids of the functional ghrelin peptide 
are encoded only by the exons 1 and 2 of the GHRL gene. The active ghrelin 
sequence immediately follows the signal peptide in human GHRL gen (Figure 
4). Although propeptides are usually processed at dibasic amino acid sites by 
prohormone convertases, the C-terminus of the human ghrelin peptide is 
processed at an uncommon P-R recognition site. PC1/3 was identified as the 
processing protease involve in the of proghrelin cleveage to yield the 28-
amino acid ghrelin peptide in the stomach44. However, in pancreas, 
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proghrelin is not processed exclusively by PC1/3, PC2 has also demonstrated 




Figure 4. From the human ghrelin/obestatin gene (GHRL) to an active 
ghrelin peptide. The transcription of the human ghrelin/obestatin gene 
yields an mRNA which is translated into a 117 amino acid ghrelin precursor. 
Protease cleavage and acylation of the ghrelin precursor result in the 28 
amino acid active ghrelin peptide (Modified from Results Probl Cell Differ. 
2010; 50:185-205). 
                                                                
45 Walia P, Asadi A, Kieffer TJ, Johnson JD, Chanoine JP. Ontogeny of ghrelin, 
obestatin, preproghrelin,and prohormoneconvertases in rat pancreas and stomach. 
Pediatr Res. 2009 Jan;65(1):39-44. 
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2.2 Ghrelin activation an its physiological consequences 
 As was previously said, to activate GHSR1a, ghrelin requires the 
attachment of a fatty acid side-chain to its serine 3 residue. This acylation is a 
rare post-translational modification; in fact ghrelin is the first case of a 
peptide hormone modified by a fatty acid46,47. Ghelin acylation is achieved by 
the ghrelin O-acyl-transferase (GOAT), an enzyme with multiple 
transmembrane domains which is a member of the membrane-bound O-
acyltransferase (MBOAT) family. GOAT had not been identified until 2008 
when two independent groups reported its identification48,49. GOAT 
distribution is similar to that of ghrelin, is predominantly found in 
gastrointestinal organs and particularly in the stomach48,49,50. GOAT 
specifically modifies the third S of human ghrelin. The replacement of the 
second, sixth, and 18th S of ghrelin by A, did not change the modified by n-
octanoic acid48, but when the third S was replaced by A, GOAT was not able 
to modify ghrelin. Something remarkable is that GOAT modifies not only S 
but also T residues. The third amino acid of frog ghrelin is T and it is also 
modified by n-octanoic acid as ghrelin’s S351. Moreover, when the third S of 
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rat ghrelin is replaced by T, GOAT modifies the replaced T by n-octanoic 
acid48, indicating what is important is the position. Besides the third position 
of the S, the G1 and P4 are also critical components of the recognition 
sequence for GOAT. While the replacement of G1 and F4 by A inhibit the acyl 
modification of the S3, the change of S2, L5, S6, or P7 by A did not have an 
effect on the acyl modification of ghrelin. In addition, N-terminal addition of 
two amino acids (S-A) significantly suppressed the acylation of the third S of 
ghrelin52. 
 Biochemically, GOAT appears to have two critical substrates, desacyl 
ghrelin (DAG) and short- to mid-chain fatty acids thioesterified with 
Coenzyme A (CoA). The ghrelin modification reaction does not occur with 
free acyl acid or a mixture of free acyl acid and CoA53. Cells expressing both 
ghrelin and GOAT synthesize S3 acylghrelin, with the acyl moiety precursors 
derived from fatty acids ranging from acetate (C2) to tetradecanoic acid 
(C14)49. However, the main molecular form of gastric ghrelin is modified by 
n-octanoic acid and other acyl-modified forms of ghrelin are only found at 
low levels54,55. Interestingly different ghrelin truncates and derivates (GSSFL-
NH2, GSAFL-NH2, GSSFL-COOH, GSS(C8:0)FL-NH2 and GSS (diaminopropionic 
acid) FL-NH2) has exhibit the ability to inhibit GOAT activity and subsequently 
the n-octanoyl modification of ghrelin52. On the other hand, the optimal pH 
for GOAT activity is between 7 and 853. However, the optimal pH of the 
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processing protease PC1/3 is rather acidic as well as the pH in the secretary 
granules (pH5–6). This suggests that the acyl-modification of ghrelin should 
occur before protease cleavage. In other words, ghrelin seems to be 
modified in the forms of preproghrelin, a 117 amino acids peptide of 13,3 
kDa which yields ghrelin and obestatin and it is also able to produce only 
proghrelin. In fact, proghrelin has been shown to be modified by n-octanoic 
acid44 (Figure 4).  
 When is acylated, ghrelin is capable of stimulate GH release from 
the anterior pituitary gland. However, in response to fasting or prolonged 
food restriction ghrelin is also produced from the stomach increasing its 
circulating levels and activating the orexigenic neural circuits. Subsequently, 
ghrelin has also shown the capacity of act in the brain to regulate numerous 
central and peripheral actions, including stimulation of gut motility and 
gastric acid secretion, modulation of sleep, taste sensation and reward 
seeking behavior, regulation of glucose metabolism, suppression of brown 
fat thermogenesis, modulation of stress and anxiety, protection against 
















Figure 5: Summary of ghrelin-mediated physiological effects in humans 





3.0 ASSOCIATED SIGNALING TO THE SYSTEM GHRELIN/GHSR1A  
3.1 G-proteins dependent signaling 
 GPCRs interact with heterotrimeric G proteins composed of α, β and 
γ subunits that are GDP bound in the resting state. Agonist binding triggers a 
conformational change in the receptor, which catalyses the dissociation of 
GDP from the alpha subunit followed by GTP-binding to Gα and the 
dissociation of Gα from Gβγ subunits56. In this process three cellular regulators 
are involved. First, the RGS (regulator of G protein signaling) proteins 
stimulate the GTPase activity of the Gα subunit to hydrolyze GTP to GDP 
more quickly and terminate the signaling event. Second, GDI (guanine 
dissociation inhibitor) prevents the release of GDP from the G protein and 
stabilizes the Gα subunit in the inactive GDP-bound conformation. Third, GEF 
(guanine exchange factor) interacts with Gα and stimulates the exchange of 
GDP for GTP to accelerate the generation of the active form of the 
receptor57,58,59. Following the receptor activation, the GEF domain 
allosterically induces the G protein’s GTPase activity, facilitating the 
hydrolysis of GTP to GDP at the Gα subunit. In the cycle of G protein 
activation, the GDP/GTP exchange and the GTP hydrolysis are two limiting 
steps. Once activated, the G protein subunits dissociate from the receptor, as 
well as each other, to yield a Gα-GTP monomer and a Gβγ dimer, which 
                                                                
56 Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 
2007 Feb;7(2):79-94. 
57 Siderovski DP, Willard FS. The GAPs, GEFs, and GDIs of heterotrimeric G-protein 
alpha subunits. Int J Biol Sci. 2005;1(2):51-66. 
58 Sato M, Blumer JB, Simon V, Lanier SM. Accessory proteins for G proteins: partners 
in signaling. Annu Rev Pharmacol Toxicol. 2006;46:151-87. 
59 Urano D, Jones JC, Wang H, Matthews M, Bradford W, Bennetzen JL, Jones AM.G 




activate intracellular signaling proteins60,61. The target functional proteins 
directly depend on the subunit type which is activated. Gαs stimulates 
adenylate cyclase, leading to cAMP (cyclic adenosine monophosphate)-
mediated responses whereas Gαi/o inhibits adenylate cyclase and the 
subsequent cAMP accumulation. On the other hand, Gαq/11 activates 
phospholypase C (PLC) leading to inositol tris-1,4,5-phosphate (IP3) and 
dyacilglycerol (DAG), while Gα12/13 activates Rho guanine exchange factors, 
triggering the kinases associated to Rho and cytoskeletal rearrangement. The 
Gβγ subunits have also been shown to regulate signaling pathways such as 
calcium release, adenylate cyclase or MAPK62,63,64.  
 In the case of the GHSR1a, Gαq/11, Gαi/o, Gαs and Gα12/13 are involved in 
the ghrelin-associated signaling. The first interaction of GHSR1a with G 
proteins was described in somatotrophs where through Gαq/11 the ghrelin 
receptor activates PLC with the subsequent inositol phosphate activation and 
Ca2+ mobilization1,65. Evidence of activation of Gαs, and thus, activation of 
adenylate cyclase and protein kinase A (PKA), has been reported for neurons 
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in the arcuate nucleus66. In addition, Gαi/o coupling has been demonstrated in 
guanosine 59-O-(3-thiotriphosphate) assays in model systems67, as well as, in 
isolated lipid discs68,69. Moreover, in pancreatic islets, interaction of GHSR1a 
with the somatostatin receptor SST5 results in coupling through Gαi/o70. 
Finally, the activation of RhoA kinase via Gα12/13 in response to ghrelin is 
observed in transfected cells. The combined actions of Gαq and Gα12/13 are 
responsible for the majority of the ghrelin-induced activation of serum 
response element (SRE)8,34. However, it still has not been described any 
GHSR1a associated signaling pathway mediated by Gβγ subunits. 
 
3.2 β-arrestins dependent signaling 
Arrestins were initially discovered in the visual system and include 
four mammalian members divided into two groups, the visual arrestins 
(arrestin-1 in rod cells and arrestin-4 in cone cells) and the non-visual 
arrestins (β-arrestin1 and β-arrestin2, also called arrestin-2 and arrestin-3, 
respectively). Arrestins were named on the basis of their ability to arrest or 
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switch-off the coupling of GPCRs to G proteins and its subsequent signaling. 
However, while all four arrestins terminate G protein signaling, it is now 
evident that the two β-arrestins which are ubiquitously express, are also able 
to function as scaffold proteins promoting GPCR internalization, degradation 
and recycling, as well as interact with many protein partners and protein 
kinases, leading to the phosphorylation of numerous intracellular targets in 
an alternative signaling independent of G proteins71,72. Among the β-arrestin-
mediated signaling mechanisms could be found stress fiber formation via 
RhoA; inhibition of NF-κB gene expression through IκB stabilization; protein 
phosphatase 2A (PP2A)- mediated dephosphorylation of Akt with the 
consequent activation of glycogen synthase kinase3 and dopaminergic 
behavior control; phosphatidylinositol 3-kinase (PI3K)-mediated 
phospholipase A2 activation and increased vasodilation through GPR109A; 
induction of protein translation and antiapoptotic effects by extracellular 
signal-regulated kinases (ERKs) regulation; Kif3A-dependent trafficking and 







                                                                
71 Ostermaier MK, Schertler GF, Standfuss J. Molecular mechanism of 
phosphorylation-dependent arrestin activation. Curr Opin Struct Biol. 2014 
Dec;29:143-51. 
72 Kang DS, Tian X, Benovic JL.Role of β-arrestins and arrestin domain-containing 
proteins in G protein-coupled receptor trafficking. Curr Opin Cell Biol.2014 Apr;27:63-
71. 
73 Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of β-arrestin-biased 







Figure 6. Summary of β-arrestin-dependent signaling at GPCRs (Extracted 




 The structure of all arrestins family members has been solved using 
X-ray techniques. All arrestins share two major domains, the N-terminal and 
the C-terminal, each composed of a seven anti-parallel β-sheets connected 
by short flexible loops. Both domains are connected by a region which acts 
like a hinge via loops at the pseudo two-fold rotation axis of the molecule. 
Arrestins also have a C-tail which is connected by a flexible linker to the C-
domain and contains a short β strand that interacts with a lateral β strand of 
the N-domain. The overall structure is stabilized by a polar core of buried salt 
bridges and by a three-element interaction involving the first β strand, an α-
helix in the N-domain and the C-terminal tail74,75,76,77. The interaction of 
charged residues from the amino terminus, N-domain, C-domain, and C-
terminal tail maintain the different parts of the molecule together to 
preserve the basal conformation. The polar core is highly conserved within 
all four arrestins, suggesting that this structural element is critical for 
arrestins function78,79,80. During its interaction with a GPCR, arrestins adopts 
several conformations (Figure 7). Firstly, arrestins are mobilized from dimeric 
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or tetrameric storage in its basal conformation. Then, arrestins are pre-
activated by a C-tail exchange mechanism of C-termini from arrestin and 
phosphorylated C-terminus of its GPCR. In this pre-activated state, arrestins 
interacts with additional sites in the activated receptor and, potentially, 
induces further conformational changes to form a high affinity GPCR–arrestin 
complex. Loss of the agonist does not necessarily imply immediate complex 
dissociation and a low-affinity complex can be also formed on 
phosphorylation-independent pathways. Despite being associated or 
dissociated from different receptor states, arrestins have structurally similar 
conformations. However, monomeric arrestins are able to form low-affinity 
complexes with either activated or phosphorylated receptor adopting two 





Figure 7. Arrestin activation mechanism (Extracted from Curr Opin Struct 
Biol. 2014 Dec;29:143-51) 
 
 Additionally to the classic G protein-mediated signaling, GHSR1a has 
also demonstrated be able to act through signaling pathways mediated by β-
arrestins. Non-visual arrestins, β-arrestin1 and β-arrestin2, has shown the 
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ability of act as adaptor proteins that function to regulate GHSR1a signaling 
and trafficking.  The interplay of G-protein and β-arrestin signaling largely 
determines the cellular consequences of the GHSR1a activation8,81,82. 
 
β-arrestins activation  
 As was described above, the binding of arrestins to activated 
receptors, in order to establish high-affinity complexes, is determined by the 
phosphorylated conformation of GPCRs. Phosphorylation of GPCRs is one of 
the most important post-translation modifications mediated by agonist 
stimulation. Once GPCRs are activated, they are rapidly phosphorylated by G 
protein-coupled receptor kinases (GRKs). These kinases initiate the 
homologous desensitization of activated GPCRs through the phosphorylation 
of S or T residues located primarily in the carboxyl terminus of the receptors, 
but also in the intracellular loops. The covalent modifications produced 
mediate receptor desensitization as well as provide a mechanism by which 
receptors can engage with β-arrestins and trigger specific downstream 
signaling pathways83,84. 
In contrast to the large number of GPCRs, there are only seven 
members in the GRK family, and of those, only four GRKs (2, 3, 5 and 6) are 
ubiquitously expressed and thus, primarily responsible for the 
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phosphorylation of most GPCRs. The remaining three GRKs are tissue 
specific, GRK1 and GRK7 expression is confined to the retina and GRK4 
highest expression was found in the testes85. Among the ubiquitous GRKs, 
GRK2 and 3 share a pleckstrin homology domain and need interactions with 
Gβγ to be bounded to the membrane; on the contrary, GRK5 and 6 are 
constitutively localized to the membrane due to their own modifications like 
palmitoylation86,87. Despite the differences, all GRKs have a conserved 
structural core comprising a protein kinase domain inserted into a loop of 
the regulator of G protein signaling homology (RH) domain. The RH domain 
act as an intramolecular scaffold maintaining the small lobe of the kinase 
domain in a competent state to phosphorylate activated GPCRs. 
Consequently, the kinase domain does not require phosphorylation on its 
activation loop for full activity. The first ∼20 amino acids of GRKs are also 
highly conserved and seem to be critical for GPCR and phospholipid-
stimulated autophosphorylation, but the disorganization of this region in the 
known GRKs structures keeps its molecular role unclear. GRKs have also 
demonstrated to share a C-terminal extension of the kinase domain 
characteristic of the AGC kinase family, which contributes residues to the 
active site cleft. Although this extension is not fully ordered in most GRKs 
structures, when this region was mutated in GRK2 and GRK1 the receptor 
phosphorylation was dramatically inhibit, consistent with the idea that this 
element may be regulating kinase activity as it does in other AGC 
kinases88,89,90. GRKs probably recognize certain structural determinants in the 
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activated receptors, but a consensus GRK target sequence motif in the GPCRs 
is not fully established because the primary sequences of GPCRs are poorly 
conserved. Furthermore, each GRK can phosphorylate different S and T 
residues of the same receptor, and this phosphorylation pattern can be 
biased by the receptor conformation induced by the bound ligand. 
Consequently, the action of different receptor kinases could provide a 
unique phosphorylation signature on the receptor. The specific GRK 
phosphoacceptors activated on the receptors can act like a barcode 
determining the β-arrestin conformation and the subsequent β-arrestins 
action on downstream signaling pathways. The detail map of the 
phosphorylation residues of a GPCR targeted by individual GRKs and the 
understanding of how these sites regulate the specific functional 
consequences of β-arrestin engagement may aid in the discovery of 
therapeutic agents targeting individual β-arrestin functions91,92. Despite the 
importance of known the phosphorylation status of a GPCR to better 
understand its function and the associated signaling, until now, the 
activation of the GHSR1a and the key pieces involved on it, remain to be 
discover. 
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Desensitization and Endocytosis 
 GHSR1a without ghrelin is mainly localized at the plasma membrane 
but it is rapidly desensitizes after stimulation. The ghrelin/GHSR1a complex 
progressively disappears from the plasma membrane after 20min. Ghrelin-
dependent GHSR1a desensitization is not mediated by protein kinase C, 
suggesting that the major cellular mechanism mediating desensitization 
might be phosphorylation by GRKs. Moreover, activation of the GHSR1a 
leads to recruitment of β-arrestins, in a G-protein coupling independent 
manner, hinting that GHSR1a endocytosis and internalization should be 
mediated by β-arrestins. However, internalization of the ghrelin receptor can 
occur in a ghrelin-independent manner, which is dependent on receptor 
constitutive activity and domains within the C-terminal tail but not β-arrestin 
dependent3,36,68,93,94.  
For GPCRs internalization two main pathways via clathrin-coated 
pits and through caveolae have been described. However, a number of 
studies reported that GHSR1a seems to internalize only via clathrin-coated 
pits. Firstly, potassium depletion decreases the number of surface clathrin-
coated pits and inhibits GHSR1a internalization. Secondly, activation of the 
ghrelin receptor leads to the recruitment of the clathrin adaptor-related 
protein complex 2 (AP2). Thirdly, the mutation of a clathrin-binding domain 
found on β-arrestins [β-arrestin (319-418)] increases significantly the 
expression of GHSR1a on the cell surface, indicating that internalization is 
dependent on the interaction between β-arrestin and clathrin68,95,96. After 
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internalize via clathrin pathway into vesicles, GHSR1a could either be sorted 
into endosomes to be recycled back to plasma membrane or, may be 
degraded within lysosomes. The evidence indicates that GHSR1a dissociates 
from ghrelin in the acidified endosomal compartments and it is recycled to 
the plasma membrane. After 20min exposure to ghrelin, GHSR-1a colocalize 
with the early endosome marker EEA1 but it fails to colocalize with the 
lysosomal marker cathepsin D at 60min despite being accumulate in the 
perinuclear region. Furthermore, GHSR1a reappears in the membrane after 2 
hours of ghrelin treatment and the recycling is prevented using inhibitors of 
endosomal acidification, NH4Cl and concanamycin A, which retain the 
ghrelin/GHSR1a complex inhibiting ghrelin degradation. A remarkable point 
is that the GHSR1a recycled from the endosomes has shown a complete 
restoration of binding capacity and functionality on the cell surface96.  
 The desensitization of the GHSR1a can be prevented by unsaturated 
fatty acids which block its internalization, highlighting the importance of 
membrane composition for GHSR activation and desensitization. Free fatty 
acids improve GHSR1a sensitivity suppressing ghrelin-induced internalization 
by uncoupling the receptor from the endocytic pathway. Consequently, 
GHSR1a is retained on the cell surface, where it can continue to signal in 
response to ghrelin96. 
 
Kinases activation 
 Like other GPCRs, the GHSR1a shows an alternative signaling 
mediated by β-arrestins independently of G proteins. β-Arrestins, through 
ghrelin-induced GHSR1a activation, are able to activate various kinases such 
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as Akt and MAPKs. MAPKs are protein kinases specific of serine, threonine 
and tyrosine amino acids which belong to the CMGC family (named after the 
initials of some members). MAPKs are involved in directing cellular responses 
regulating cell functions such as proliferation, gene expression, 
differentiation, mitosis, cell survival and apoptosis. Among the major MAPKs 
can be found: the extracellular signal-regulated kinases (ERKs), Jun amino-
terminal kinases (JNKs) and p38 kinases. On the other hand, Akt is a S/T-
specific protein kinase that plays a key role in multiple cellular processes like 
glucose metabolism, apoptosis, cell proliferation, transcription and cell 
migration97.  
 Ghrelin mediated GHSR1a activation trigger Akt activation with cSrc 
functioning as a switch that initiates both pathways associated to Akt, the 
Gi/o protein–dependent pathway and the β-arrestin–scaffolded complex. The 
Gi/o-protein activates PI3K which translocates Akt to the plasma membrane 
through the binding of its pleckstrin homology domain to the second 
messenger PtdIns(3,4,5)P3 (PIP3). In the membrane, Akt is phosphorylated at 
Y by cSrc with the subsequent phosphorylation of Akt A loop in T308 by PDK1 
and at S473 of the hydrophobic motif by mTORC2. The second signaling 
pathway mediated by β-arrestins starts after receptor activation and it 
involves the recruitment of at least β-arrestin 1, β-arrestin 2, c-Src and Akt. 
cSrc also regulates the phosphorylation and activation of  the tyrosine 
phosphatase of SHP1 in both signaling pathways. cSrc phosphorylates the 
SHP1 C-terminus (Y536), which exerts an inhibitory effect on PI3K and Akt 
giving to cSrc its switch ability (Figure 8)82,98.  
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Figura 8. Ghrelin-mediated signaling to Akt.  Ghrelin binding to GHSR1a, 
through Gi/o protein, activates PI3K and consequently, the second messenger 
PIP3. Akt translocates to the plasma membrane by binding to PIP3, where it 
is phosphorylated at Y by the membrane-bound cSrc. cSrc activation induced 
phosphorylation of SHP1, attenuation of p85 subunit from PI3K and PDK1, 
and phosphorylation of Akt. SHP1 activation regulates cSrc activity by 
attenuation of Y416 phosphorylation. Once the receptor is activated, a 
second signaling pathway is mediated by β-arrestins 1 and 2, involving the 
recruitment of GHSR1a, cSrc, SHP1, and Akt into a β-arrestins complex 
(Extracted from Mol Biol Cell. 2011 Nov;22(21):4182-91). 
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 On the other hand, ghrelin has also shown the ability to activate the 
MAPK kinase ERK1/2 through GHSR1a. ERK1/2 phosphorylation from GHSR1a 
activation is interplay of three signaling pathways which combine G protein 
and β-arrestins signaling. The pathway mediated by β-arrestins 1 and 2 
requires the entry of the receptor into a multiprotein complex that at least 
compromises β-arrestins, Src, Raf-1 and ERK1/2. The Gq/11-dependent 
cascade involves PKCα/β and Src and the third pathway Gi/o-dependent 
implicates PI3K, PKCε, and Src. Moreover, G protein dependent signaling 
pathways are involved in the β-arrestin-mediated ERK1/2 activation and this 
activation differs in their temporal and spatial distributions. Upon ghrelin 
stimulation of GHSR1a receptor, Gq/11- and Gi/0- protein mediated ERK1/2 
activation is immediately, while β-arrestin-dependent ERK1/2 activation is 
relatively slow but persistent (Figure 9)81,94. 
Figure 9. Proposed model for ghrelin-induced ERK1/2 activation. In HEK293 
cells ghrelin, through GHSR1a, activates three pathways. First, the Gq/11-
dependent pathway involves the consecutive activation of PIPLC, PKCα/β 
isoforms, and Src. Second, the Gi/0 dependent-pathway is mediated by PI3K, 
PKCε, and Src. Finally, the β-arrestins-mediated pathway involves 
recruitment of Src, Raf-1, and ERK1/2 to a β-arrestin complex with GHSR1a. 
This pathway is mediated by G-protein-regulated effectors such as PKCα/β 
(dotted lines) (Extracted from J. Cell. Physiol. 2007; 213: 187–200). 
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4.0 ASSOCIATED FUNCTIONALITY TO GHSR1a SIGNALING 
4.1 G proteins-mediated Ca+2 release and GH secretion 
 Ghrelin feeding control is mediated in its first step by Ca+2 releases. 
Two calcium signaling pathways have been described for GHSR1a activation. 
In the first cascade, the Gαq subunit releases upon ghrelin administration 
activates cyclic adenosine monophosphate (cAMP) in the in the 
hypothalamic arcuate nucleus (ARC) and subsequently protein kinase A 
(PKA). The activated PKA induces CREB phosphorylation, which inhibits 
potassium channels. When the potassium channels are closed, the cell 
depolarizes and N-type calcium channels releases Ca+2 from intracellular 
stores66. The second pathway is Gαs-dependent and it is dependent on 
calcium influx through the N-type calcium channel. In the neuropeptide Y 
(NPY)-containing neurons calcium induced phospholipase C (PLC) promotes 
phosphatidylinositol-4,5-bisphosphate (PIP2) hydrolysis in the cell 
membrane. This process increases intracellular level of calcium in two ways. 
Firstly, PIP2 is able to activate diacylglycerol (DAG), which phosphorylates 
protein kinase C (PKC) causing the opening of L-type calcium channels. 
Secondly, PIP2 has also shown the capacity to activate inositol trisphosphate 
(IP3) inducing calcium release from the endoplasmic reticulum99. 
 After being release, Ca+2 mediates the production of nitric oxide 
(NO) which is an important regulator of energetic homeostasis and a key 
piece in appetite control. Ca+2-dependent nitric oxide synthase (NOS) 
generates NO from arginine which stimulates guanylyl cyclase (GC) with the 
subsequent cyclic guanosine monophosphate (cGMP) activation. Nitric oxide 
action in the increase in appetite induced by ghrelin is supported for several 
discoveries. Firstly, feeling of satiety and hunger was correlated with changes 
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in hypothalamic NOS concentration and inhibition of NOS activity resulted in 
an increase in food intake in rodents. Secondly, ablation of ghrelin increases 
NOS concentration and rise hypothalamic activity of NOS after 
intraventricular injections of NPY. Thirdly, central injections of ghrelin 
increase the concentration of NOS in the hypothalamus and exogenous 
ghrelin effect on feed intake was neutralized by the NOS inhibitor l-NG-
nitroarginine methyl ester (l-NAME). Due to NO is a gas, it easily leaves the 
neurons and stimulate cGMP formation in other cells connecting CNS with 
peripheral tissues. Moreover, a high level of cytosolic calcium in the 
somatotropic cells of the hypophysis causes GH release37,100,101,102,103,104. 
 
4.2 AMPK: a master enzyme of metabolic regulation 
 Regulation of appetite, energy homeostasis, growth hormone (GH) 
secretion and body weight is due to a coordinated negative feedback 
between central neural circuits and peripheral target tissues. The synthesis 
and release of peripheral metabolic hormones is a key part of this negative 
feedback action. The main regulating appetite hormones are leptin from 
adipose tissue and ghrelin from the stomach.  
                                                                
100 Morley JE, Alshaher MM, Farr SA, Flood JF, Kumar VB. Leptin and neuropeptide y 
(npy) modulate nitric oxide synthase: further evidence for a role of nitric oxide in 
feeding. Peptides 1999;20:595–600. 
101 Morley JE, Kumar VB, Mattammal M, Villareal DT. Measurement of nitric oxide 
synthase and its mrna in genetically obese (ob/ob) mice. Life Sci 1995; 57:1327–31. 
102 Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE. Ghrelin-induced feeding is 
dependent on nitric oxide. Peptides 2003;24:913–8. 
103 Anderson LL, Jeftinija S, Scanes CG.Growth hormone secretion: molecular and 
cellular mechanisms and in vivo approaches. Exp Biol Med (Maywood). 2004 
Apr;229(4):291-302. 
104 Gomperts BD, Tatham PER, Kramer IM. Nitric oxide synthase. In: Signal 
transduction. London: Elsevier Inc.; 2009. 
Introduction 63 
 
 In the hypothalamic arcuate nucleus (ARC) GHSR1a is activated by 
ghrelin increasing the coexpressed orexigenic peptides neuropeptide Y (NPY) 
and agouti-related peptide (AgRP). But also in the ARC, leptin is able to 
activate the proopiomelanocortin precursor protein (POMC) which is cleaved 
into the potent anorexigenic melanocyte-stimulating hormone105,106. For this 
reason, negative energy balance increases ghrelin amount in plasma 
releasing hypothalamic AMP-activated protein kinase (AMPK) and increasing 
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Figure 10. Hypothalamic circuits governing appetite. NPY/AgRP neurons in 
the ARC (blue) receive hormonal inputs from the plasma. While ghrelin 
activates NPY/AgRP (green arrow), leptin suppresses it (yellow dashed line). 
NPY/AgRP neurons inhibit POMC neurons (dashed green line). Leptin 
suppresses food intake by directly activating POMC neurons (yellow arrow) 
and indirectly by activating leptin receptor neurons in the ventromedial 
hypothalamic nucleus (yellow arrow) that send excitatory glutamatergic 
inputs onto POMC neurons. In the paraventricular nucleus, the anorexic 
POMC peptide, (aMSH, orange), activates the melanocortin 4 receptor 
(MC4R) to suppress food intake. NPY peptide release (blue) in the PVN acts 
on Y1 and Y5 receptors and AgRP (purple) acts as an antagonist at the MC4R 
to prevent the anorectic actions of aMSH. Together this results in increased 
food intake (Extracted from Mol Cell Endocrinol. 2013 Feb 25;366(2):215-23). 
 
 Due to its central position in the signaling pathways AMPK is a 
master enzyme of metabolic regulation. AMPK is a S/T protein kinase which 
acts as an intracellular energy sensor and whose activation requires 
phosphorylation of T172 within the T loop region of the catalytic α subunit. 
In response to an increase in AMP/ATP ratio AMPK is phosphorylated and 
switches off anabolic pathways which consume ATP (synthesis of lipids, 
carbohydrates and proteins) and switches on catabolic pathways which 
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produce ATP (glycolysis, glucose uptake, fatty-acid oxidation and 
mitochondrial biogenesis)109.  
 
 AMPK action in the CNS 
 The ghrelin-induced elevation of Ca+2 concentration in the cytosol 
leads to the activation of calmodulin-dependent protein kinase kinase2 
(CaMKK2), and subsequent AMPK phosphorylation in the ARC. However, 
ghrelin is able to activate AMPK not only in the ARC but also in the 
ventromedial hypothalamic nucleus (VMH) independently. Additionally, a 
second pathway for ghrelin-induced AMPK activation has been described 
where ghrelin specifically triggers a central SIRT1 (NAD-dependent protein 
deacetylase sirtuin-1)/p53 pathway that is essential for its orexigenic action, 
but not for the release of growth hormone110,111,112,113. 
The first downstream pathway describes in the ARC and VMH for 
ghrelin-mediated AMPK activation was a mitochondrial mechanism. In 
response to ghrelin, AMPK increases fatty acid oxidation in order to produce 
ATP. During this oxidation, hypothalamic mitochondrial respiration is 
enhanced generating an excess of reactive oxygen species (ROS) which is 
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buffer or scavenge by uncoupling protein 2 (UCP2). Ghrelin activation of this 
mechanism involves after AMPK activation, acetyl CoA carboxylase 
phosphorylation, inhibition of malonyl CoA and increased carnitine palmitoyl 
transferase 1 (CPT1) activity in a UCP2 dependent way. This Ghrelin-AMPK–
CPT1–UCP2 action is critical for mitochondrial biogenesis and electrical 
activation of NPY AgRP neurons, for trigger synaptic plasticity of POMC 
expressing neurons and for promote food intake. This signaling pathway 
connects neuronal function of G protein coupled receptor activity in 
mitochondria and the associated behavior111,112. Other candidate to mediate 
the effects of ghrelin downstream of AMPK is the mammalian target of 
rapamycin complex 1 (mTORC1), a multimolecular complex which is 
activated trough S6 kinases (S6K) and contains the serine/threonine protein 
kinase mTOR. Ghrelin-induced AMPK activation decreases mTORC1 activity. 
However, fasting or exogenous ghrelin administration increases mTORC1 
activity in the ARC rather than inhibited it114,115. This may be due to mTORC1 
activation is independent of AMPK to increase food intake or because AMPK 
exerts its metabolic effects through other molecular targets. The role of 
mTORC1 in the VMH remains to be unclear. Nonetheless, taking into account 
that fatty acid synthesis inhibitors decrease food intake by increasing 
hypothalamic mTORC1, the fact that fasting inhibit S6 phosphorylation in the 
VMH and that mTORC and AMPK action is the opposite, it would be expected 
that ghrelin will inhibit mTORC1 activity contrary to what happen in the 
ARC114, 116. Thereby, the role of mTORC1 regulation of food intake and energy 
                                                                
114 Villanueva EC, Münzberg H, Cota D, Leshan RL, Kopp K, Ishida-Takahashi R, Jones 
JC, Fingar DC, Seeley RJ, Myers MG Jr. Complex regulation of mammalian target of 
rapamycin complex 1 in the basomedial hypothalamus by leptin and nutritional 
status. Endocrinology. 2009 Oct;150(10):4541-51. 
115 Watterson KR, Bestow D, Gallagher J, Hamilton DL, Ashford FB, Meakin PJ, Ashford 
ML. Anorexigenic and orexigenic hormone modulation of mammalian target of 
rapamycin complex 1 activity and the regulation of hypothalamic agouti-related 
protein mRNA expression. Neurosignals. 2013;21(1-2):28-41. 
116 Proulx K, Cota D, Woods SC, Seeley RJ.Fatty acid synthase inhibitors modulate 
energy balance via mammalian target of rapamycin complex 1 signaling in the central 
nervous system. Diabetes. 2008 Dec;57(12):3231-8. 
Introduction 67 
 
balance in the hypothalamus it would depend upon the neuronal populations 
that are specifically targeted by ghrelin117.  
 
Peripheral action of AMPK signaling 
 As was previously remarked, the central neural circuits are 
connected to peripheral target tissues. For this reason, ghrelin induced 
AMPK signaling pathways were studied in different tissues. In the pancreas 
for example, ghrelin decreases insulin secretion via AMPK-UCP2 signaling 
pathway as well as it has been demonstrated reduced the amount of 
pancreatic polypeptide secreted which inhibits appetite118. Ghrelin has also 
been related with the AMPK activity in the regulation of bone metabolism, 
bone nodule formation and maintenance of bone mass119. A recent study has 
demonstrated a potential protective role of ghrelin against myocardial injury 
and apoptosis induced by endoplasmic reticulum stress partially through a 
GHSR1a/CaMKK/AMPK pathway120. Ghrelin administration in rats attenuated 
NAFLD-induced hepatic injury, inflammation and apoptosis, partly through 
restoration of LKB1/AMPK and PI3K/Akt pathway121. Furthermore, ghrelin 
reduced tumor necrosis factor (TNFα) and IL-6 levels in obese mice 
attenuating lipotoxicity and regulating autophagy via AMPK/mTOR and 
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inhibiting NF-κB translocation into the nucleus122. Moreover, ghrelin 
contributes to the cytoprotection during hepatic ischaemia/reperfusion 
injury blocking the induced AMPK upregulation. However, it remains to 
clarify if the ghrelin action is direct or indirect on hepatocytes123. It is 
precisely the action in the inflammatory process the main peripheral action 
mediated by ghrelin via AMPK known to date. 
 Tissue inflammation mediated by immune cell in the adipose tissue, 
liver and skeletal muscle plays increase insulin resistance which may result in 
develop of obesity and diabetes124. Obesity associated inflammation causes 
inflammatory responses in the hypothalamus by a classic reaction pathway 
which involves the transcription factor NF-κB. Lipid accumulation in non-
adipose tissue promotes the degradation of nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, alpha and betta (IκB α and IκB 
β), resulting in the translocation of NF-κB into nucleus and subsequently 
secretion of TNFα, inflammatory cytokines such as interleukins(IL)- 6, 8, 10, 
1β or VEGF120 and MCP1 adipokines. Ghrelin action in T cells, monocytes 
and microglia inhibit NF-ĸB decreasing the expression and production of 
proinflammatory cytokines and TNFα125,126,127. Despite this, it was described 
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the cell specific action of ghrelin as a pro-inflammatory peptide inducing, 
rather than reducing, NF-ĸB expression and proinflammatory IL-8, VEGF120 
and MCP1 secretion128,129,130. This controversial ghrelin action on 
inflammatory response was related with direct action of AMPK/mTOR 
signaling on the peripheral tissues and central nervous system.  
 AMPK was further described as point of convergence between the 
ghrelin and cannabinoid signaling pathways. Cannabinoids and ghrelin 
stimulate AMPK activity in the hypothalamus and heart, and both inhibit liver 
and adipose AMPK activity131. In addition, the central ghrelin treatment 
affects peripheral AMPK activity via the involvement of central CB1, 
suggesting a CNS-liver/adipose tissue neural link and a close interaction of 
the two systems in the regulation of metabolic pathways132,133. 
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4.3 Akt signaling, more than adipogenic effect 
 During the last decades obesity treatment is becoming a global 
concern because it is rising at an alarming rate in western countries while 
development of new efficient drugs is being much slower. Excessive adiposity 
is related to many chronic diseases as insulin resistance, type 2 diabetes 
mellitus, cardiovascular disease, liver steatosis or cancer. Ghrelin signaling 
has increasingly been recognized as a key regulator of obesity and its 
derivate pathologies9. Ghrelin is the only known circulating orexigenic 
hormone predominantly produced by the stomach in response to the 
negative energy balance. Circulating levels of ghrelin are augmented in 
response to fasting or prolonged food restriction. The total ghrelin levels are 
decreased in obesity, insulin resistance and diabetes type2134. However, 
ghrelin circulates in two distinct isoforms, acylated ghrelin and desacyl 
ghrelin (DAG) and a more detail study of circulating concentrations has 
shown that the acylated ghrelin, which is the only able to activate the 
GHSR1a, was increased in obesity, obesity-associated type2 diabetes. Ghrelin 
has also show the capacity of increases directly insulin stimulated glucose 
uptake in adipocytes135, 136. 
 Ghrelin effect on adiposity is mediated by PI3K/Akt signaling. As was 
previously described, upon ghrelin stimulation, GHSR1a activates Akt 
through the Gi/o protein-dependent pathway and the β-arrestins signaling 
with cSrc functioning as a switch between both. In addition, β-arrestins 
depletion leads to a significant reduction of the Akt downstream effectors 
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mammalian target of rapamycin complex 1 (mTORC1) and the ribosomal 
protein S6 kinase beta-1 (S6K1), as well as inhibits lipid accumulation 
decreasing the adipogenic factors C/EBPβ, C/EBPδ, C/EBPα 
(CCAAT/enhancers binding protein α, β, δ) and PPARγ (peroxisome 
proliferator-activated receptor γ)98,137. Moreover, in differentiating omental 
adipocytes, stimulation with ghrelin has also produced a significantly 
increase in PPARγ  and SREBP1 (sterol-regulatory element binding protein-1) 
mRNA levels, as well as several proteins related with fat storage, including 
acetyl-CoA carboxylase, fatty acid synthase, lipoprotein lipase and 
perilipin138. Consequently, all of these results together confirm that ghrelin 
stimulates intracytoplasmatic lipid accumulation via Akt activation. 
 Apart from the implication in the lipid storage in the adipose tissue, 
mitogenesis and apoptosis are also regulated by GHSR1a through AKT 
signaling. Ghrelin administration in rats attenuates NAFLD-induced hepatic 
injury, inflammation and apoptosis, partly through PI3K/Akt pathway. 
Isoproterenol-induced lipolysis is prevented by ghrelin triggered signaling 
pathways that involves PI3Kγ/AKT and PDE3B as key downstream 
effectors121,139. Neuroprotective mechanism of ghrelin after injury in rat 
hippocampus was associated with the promotion of PI3K/Akt signaling 
pathway and the inhibition of JNK signaling. Moreover, the activation of the 
JNK pathway might depend on the activation of PI3K/Akt and the activation 
of Akt has also been related with increased ratio of Bcl-2/Bax and inhibition 
of cytochrome c release from mitochondria with the subsequent prevention 
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of caspase-3 activation.  Accordingly, ghrelin promotes survival of 
hippocampus neurons through Akt pathway140,141,142. This antiapoptotic 
effect have also been demonstrated in cardiomyocytes, endothelial cells, 
hepatocytes, porcine ovarian follicular cells and pancreatic β-cells143,144,145,146. 
The proliferative effect in adult rat hippocampal cells and in neural 
progenitor cells (NPCs) involves multiple signaling pathways, such as 
MEK/ERK1/2, PI3K/Akt, and Jak2/STAT3. This mitogenic action was also 
related to PI3K/Akt signaling in osteoblast, intestinal epithelial cells, murine T 
cells, porcine ovarian follicular cells and cancer gastric cells142,142,147,148,149,150. 
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Besides, a recent study has reported that PI3K/Akt trough eNOS/NO induces 
endothelial progenitor cell (EPC) migration151. 
 
4.4 MAPKs: proliferation and differentiation 
 In addition to the PI3K/Akt signaling, ghrelin also regulates the 
proliferation and differentiation through MAP kinases (MAPKs) signaling in a 
wide variety of cell types. MAPKs pathway is implicated in the proliferation of 
rat hippocampal neural stem cells (NSCs) in combination with the PI3K/Akt, 
and Jak2/STAT3 signaling pathways148. Activation of GHSR1a stimulates the 
proliferation of human and rat adrenal zona glomerulosa cells through a 
mechanism involving ERK1/2152. MAPKs, especially ERK1/2, are rapidly 
activated by ghrelin in preadypocites; besides, ERK inhibition significantly 
attenuates the mitogenic and anti-apoptotic effect of ghrelin in these cells153. 
In intestinal epithelial cells GHSR1a regulates mitogenesis by cross-talk with 
epidermal growth factor receptor (EGFR) and activation of PI3K/Akt; both 
these pathways converge to stimulate ERK1/2 downstream149. Moreover, a 
positive effect of ghrelin in proliferation via MAPK pathway activation has 
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been found in hepatoma, adipose, cardiomyocyte, prostate cell lines, and 
pituitary cell lines154, 155,156. 
 Through MAPKS ghrelin has also show effect on apoptosis. For 
example, ghrelin inhibits oligodendrocytes H₂O₂-induced apoptosis in part 
through ERK1/2 activation and decreasing p38MAPK157. Moreover, PI3K/Akt 
and ERK1/2 pathways have shown to share the mediation of the 
neuroprotective protective effect of ghrelin against ischemic injury or status 
epilepticus (SE), as well as the ghrelin protective effect against the serum 
deprevation-induced apoptosis of osteoblastic MC3T3-E1 cells142,147. 
Furthermore, the protective effect of ghrelin on pancreatic β-cells from 
cytokine-induced toxicity during insulitis, was also mediated by ERK1/2 and 
Akt signaling pathways158. 
 Nonetheless, ghrelin action in cardiovascular endothelial cells is 
open to discussion due a controversial effect. Some studies have reported 
the role of GHSR1a in the increase of proliferation, migration and 
angiogenesis of human dermal microvascular endothelial cells (HMVECs) and 
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cardiac microvascular endothelial cells (CMECs) via MEK/ERK and PI3K/Akt 
signaling pathways159,160. Moreover, ghrelin has also improved H9c2 
cardiomyocyte survival by suppressing the excessive autophagy through both 
ROS inhibition and mTOR induction via inhibition of AMPK and stimulation of 
p38-MAPK161. In addition, ghrelin has also demonstrated reduces aging 
deterioration of angiogenesis in HMVECs by MAPK/ ERK2 activation; induces 
endothelial progenitor cell (EPC) migration via PI3K/Akt/eNOS/NO; 
attenuates angiogenesis induced by oxLDL in HCAECs inhibiting NF-κB 
pathway; and inhibits cell apoptosis in human umbilical vein endothelial cells 
(HUVECs) via MEK/ERK1/2 and PI3K/Akt signaling pathways151,162,163,164. 
However, other in vitro studies have indicated that ghrelin can inhibit FGF-2-
stimulated angiogenesis in rat brain microvascular endothelial cells (NECs) 
and HUVECs by inhibition of tyrosin kinases (TK)/MAPK cascades165,166. 
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Furthermore, in vivo studies have shown the same controversy. On the one 
hand, ghrelin stimulates retinal angiogenesis via GHSR1a in rats and induces 
angiogenesis in rats after myocardial infarction through the enhancement of 
vascular endothelial growth factor (VEGF) and its receptors Flk-1 and Flt-1 
and inhibition of apoptosis167,168. On the other hand, a recent study reported 
that systemic administration of ghrelin did not restore angiogenesis in 
hindlimb ischemia in normal C57BL/6 mice and diet-induced obese mice169. 
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1.0 MATERIALS 
 Human ghrelin peptide and 1-5, 1-14 and 1-18 ghrelin was obtained 
from California Peptides (CA, US). Radioisotope [32P]-orthophosphate 
(specific activity 8500–9120Ci/mmol), was from PerkinElmer Life Sciences. 
Secondary antibodies were purchased from Jackson immunoresearch 
laboratories (PA, US) and the primary antibodies are listed in the Table 1. 
Antibody Use Dilution Supplier Reference 
Actin WB 1:5000 Abcam ab1801 
Akt WB 1:1000 Cell Signaling 4685 
EGFP WB 1:1000 Abcam ab111258 
ERK1/2 ICQ 1:500 Cell Signaling 9102 
ERK1/2 WB 1:1000 Cell Signaling 9102 
GAPDH WB 1:5000 Abcam ab9485 
GRK2 WB 1:1000 Novus NB110-57020 
GRK6 WB 1:1000 Abnova H00002870-M10 
HA WB 1:5000 Sigma H3663 
pAkt (S473) WB 1:1000 Novus NB100-79891 
pGRK2(S670) WB 1:1000 Abcam ab4473 
PKCα WB 1:1000 Cell Signaling 2056 
pPDK1 (S241) WB 1:1000 Cell Signaling 3061 
pPKCε (S729) WB 1:1000 Santa Cruz Biotechnology sc-12355 
pPKCγ (T514) WB 1:1000 Cell Signaling 9379 
pPKCδ(T507) WB 1:1000 Santa Cruz Biotechnology sc-11770 
pPKCη (T655) WB 1:1000 Abcam ab5798 
pPKCµ(PKD)(S916) WB 1:1000 Cell Signaling 2051 
pPKCζ(T410) WB 1:500 Santa Cruz Biotechnology sc-12894 
pPKCθ(T538) WB 1:1000 Cell Signaling 9377 
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pPKCα/β(T638/641) WB 1:1000 Cell Signaling 9375 
pERK(T202/Y204) WB 1:1000 Cell Signaling 9101 
β-arrestin 1 WB 1:1000 Abcam ab31848 
β-arrestin 2 WB 1:500 Cell Signaling 3857 
 
Unless otherwise stated, all the rest biochemicals and reagents were from 
Sigma (MO, US). 
 
2.0 METHODS 
2.1 Cell culture 
 The human embryonic kidney (HEK) 293 wild-type (WT) cell line was 
obtained from the European Collection of Cell Cultures (ECACC) and was 
maintained in DMEM (Lonza; Basilea, CH) supplemented with fetal bovine 
serum (FBS) 10% (v/v), and 100U/mL penicillin-streptomycin solution. HEKs 
293 stably transfected with GHSR1a-EGFP or GHSR1a-HA plasmids were 
maintained like WT adding 500µg/mL of G418 antibiotic.  
 The wild-type (WT), the β-arrestin 1 knockout (β-arrestin-1-/-) and 
the β-arrestin 2 knockout (β-arrestin-2-/-) murine embryonic fibroblast (MEF) 
cells, provided by Prof. Robert J. Lefkowitz (Duke University Medical Center, 
Durham, NC, US), were maintained in DMEM supplemented with 10% (v/v) 
FBS and 100U/mL penicillin-streptomycin solution.  
 The GC cell line was obtained from the American Type Culture 
Collection (ATCC) and was maintained routinely as a monolayer in DMEM 
medium supplemented with 15% (v/v) horse serum, 2.5% (v/v) FBS and 
100U/mL of penicillin-streptomycin solution. GCs stably expressing GHSR1a-
EGF were maintained like the GC WT cells adding 500µg/mL of G418 
antibiotic.  
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 3T3-L1 preadipocytes were obtained from the ATCC and were 
maintained in DMEM containing 10%(v/v) FBS and 100U/mL of penicillin-
streptomycin solution. For 3T3-L1 adipocyte differentiation, the 2-day-
postconfluent cells (day 0) were treated with 0.5mM isobutylmethylxantine 
(IBMX), 25µM dexamethasone (DEX) and 861nM insulin, ghrelin or the 
corresponding truncate in DMEM containing 10%(v/v) FBS for 72h. After 72h, 
the differentiation medium was renewed every 48h with DMEM containing 
10% (v/v) FBS and either insulin, ghrelin or the corresponding truncate 
(172nM) until the cells were used. Cultures were incubated at 37°C in a 
humidified atmosphere containing 5% CO2.  
 
2.2 Plasmids  
 The GHSR1a fused at its C terminus to enhanced green fluorescent 
protein (EGFP; GHSR1a-EGFP) in pEFGP-N1 (Clontech, CA, US) was provided 
by Prof. Catherine Llorens-Cortes (Institut National de la Sante et de la 
Recherche Medicale, College de France, Chaire de Medecine Experimentale, 
Paris, FR). The GHSR1a tagged at N-terminus with hemagglutinin (HA; 
GHSR1a-HA) in pcDNA3.1 was purchased from the cDNA resource center of 
the University of Missouri (MO, US). 
 β-arrestin 1 tagged at C-terminus with red fluorescent protein (RFP; 
β-arrestin 1-RFP) in pcDNA3.1, was provided by Prof. Robert J. Lefkowitz 
(Duke University Medical Center, Durham, NC, US) through Addgene 
(Cambridge, MA, US). β-arrestin 2 tagged with m-cherry at its C-terminus (β-
arrestin 2-cherry) was provided by PROTEX laboratory of the University of 
Leicester.  
 Renilla luciferase-tagged β-arrestin 1 (Rluc-β-arrestin 1) was 
provided by Prof. Mark Scott (Institut Cochin, Paris, FR) and β-arrestin 2 
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tagged with Rluc (Rluc-β-arrestin 2) was provided by Prof. Graeme Milligan 
(University of Glasgow, Scotland, UK). 
 Human GRK2 KO CRISPR/Cas9 and human GRK2 homology directed 
repair (HDR), were purchased from Santa Cruz Biotechnology Inc (CA,US). 
 
2.3 Site-directed mutagenesis  
 In order to generate the three GHSR1a mutants [Double mutant 
(GHSR1a-DM): S349A, T350A; Triple mutant (GHSR1a-TM): S362A, S363A, 
T366A; and, Total mutant (GHSR1a-Total):  S349A, T350A, S362A, S363A, 
T366A], mutations to the GHSR1a wild type (GHSR1a-WT) sequence were 
incorporated using the in vitro site-directed mutagenesis QuikChange 
method (Stratagene, Cheshire, UK). The method used could be summarized 
in the following steps: 
1. Using a temperature cycler the specifically design mutant 
oligonucleotide primers, each complementary to opposite strands of 
the base vector, was extended by PfuTurbo DNA polymerase. The 
cycle used was:  denaturation 98° C 2min, 18 cycles of denaturation-
anneling-elongation (98°C 30s - 55°C 1min - 68°C 8min) and a final 
elongation step of 68°C 8min.  
2. The product was treated 1h at 37°C with DpnI, a specific 
endonuclease for methylated and hemimethylated DNA, to digest 
the parental DNA template and to select the synthesized DNA 
containing the desire mutation.  
3. The DNA were transformed into DH5α supercompetent cells from 
Life technologies, Invitrogen (NY, US), ten or more colonies were 
growing overnight at 37°C and 220rpm and purified using the High 
Pure Plasmid Isolation Kit provided by Roche (Basel, CH).  
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4. The identity of the plasmids generated was verified by sequencing. 
5. One Plasmid with the right mutation was used to introduce the next 
mutation or was transformed again into DH5α supercompetent cells 
if it included all the necessary mutations.  
6. Finally, the GHSR1a mutants generated were grown in a large scale 
overnight at 37°C and 220rpm before being purified using QuiaFilter 
plasmid Maxi kit from QUIAGEN (Hilden, DE). 
In this manner, GHSR1a mutants tagged at C-terminus with either EGFP or 
HA were generated. 
 
2.4 Subcloning 
 Before being used to generate the GHSR1a mutants, the GHSR1a-HA 
plasmid tagged at C-terminus was generated from the N-terminus. The 
GHSR1a tagged at N-terminus was amplified by PCR using a forward primer 
which includes the XhoI restriction site and a reverse primer including KpnI 
restriction site and the 3xHA tag. PCR products were then subcloned into 
pcDNA3.1+. 
 To generate the GHSR1a WT and three mutants fused to enhanced 
yellow fluorescent protein (eYFP), GHSR1a-EGFP plasmids were amplified by 
PCR using primers which removed the stop codon and introduced a 5’ HinDIII 
and 3’ KpnI restriction sites. The resulting PCR products were then subcloned 
into pcDNA3.1 upstream of full length eYFP to generate C-terminal eYFP 
fusion constructs.  
 The DNA vectors containing the new constructions were 
transformed into DH5α supercompetent cells from Life technologies, 
Invitrogen (NY, US). Selected colonies of each plasmid were growing 
overnight at 37°C and 220rpm and purified using the High Pure Plasmid 
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Isolation Kit provided by Roche (Basel, CH) before verify the sequence of the 
plasmids generated. One of the plasmids including the right insert was then 
transformed again into DH5α supercompetent cells and grown overnight at 
37°C and 220rpm. Finally, the DNA was purified using QuiaFilter plasmid 
Maxi kit purchased from QUIAGEN (Hilden, DE). 
 
2.5 Cell transfections  
 The HEK293 and the MEF cells were transiently transfected with the 
GHSR1a-WT and its three mutants tagged with EGFP, using Lipofectamine 
2000 (Life Technologies, Invitrogen; NY, US), according to the manufacturer’s 
instructions to perform the immunoblot assays. All cellular assays involving 
transient transfections were only be carried out if the transfection efficiency 
was 80% or higher.  
 To perform the mass spectrometry, the silencing gene expression 
assays, the inhibition assays and the growth hormone secretion 
measurements, stably HEK293 and GC cell lines expressing GHSR1a WT-EGFP 
were generated by clone picking after 10 days under G418 selection. In both 
cases, the optimal selection antibiotic concentration, determined from the 
antibiotic kill curve previously done, was 500µg/mL. Likewise, GHSR1a cells 
lines stably expressing GHSR1a and the mutants tagged with HA at the C-
terminus were generated. The GHSR1a expression of all clones was tested by 
immunoblot before use the stably cell lines. 
 In order to ensure the same amount of transfected cells in the 32P 
labeling assays, HEK293 cell lines expressing GHSR1a-WT and the three 
mutants EGFP tagged were selected during 10 days on the basis of resistance 
to G418 (500µg/ml) and further selected using flow-assisted cell sorting.  
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2.6 CRISPR knocking down gene expression  
 To knockdown the expression of the GRK2 gene, HEK293 cells stably 
expressing GHSR1a-HA were cotransfected with human GRK2 KO 
CRISPR/Cas9 and human GRK2-HDR plasmids using Lipofectamine 2000 (Life 
Technologies, Invitrogen; NY, US),and following manufacturer’s instructions. 
CRISPR/Cas9 GRK2 KO plasmids consist of a pool of three plasmids each 
encoding the Cas9 nuclease, a GRK2-specific guide RNA and green 
fluorescent protein (GFP). On the other hand, HDR plasmid consists of a pool 
of 2-3 plasmids, each containing a homology-directed DNA repair (HDR) 
template corresponding to the cut sites generated by the GRK2 CRISPR/Cas9 
KO plasmids, a puromycin resistance gene to enable selection of stable 
knockout cells and, also contains RFP to visually confirm the transfection. 
Based on the puromycin resistance, the cells where selected during 10 days 
or more with 1µg/ml of puromycin before performed the assays. The 
puromycin concentration was determined from the antibiotic kill curve 
previously done. 
 In order to ensure the same amount of transfected cells in the 32P 
labeling assays, HEK293 cells stably expressing the GHSR1a WT and the three 
mutants tagged with HA at the C-tail were transiently cotransfected with 
human GRK2 KO CRISPR/Cas9 and human GRK2-HDR plasmids using 
Lipofectamine 2000 (Life Technologies, Invitrogen; NY, US) following 
manufacture’s instructions, selected during 10 days with puromycin (1µg/ml) 
and further selected using flow-assisted cell sorting based on the green 
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2.7 [32P] Orthophosphate labeling and GHSR1a immunoprecipitation 
 To perform GHSR1a and mutants labeling, 200,000 cells/well of 
GHSR1a-EGFP, GHSR1a-EGFP DM, GHSR1a-EGFP TM or GHSR1a-EGFP Total 
cell lines were plated in 6-well dishes 24h before experimentation and serum 
starved over night. For phosphorylation experiments, cells were washed 
three times with Krebs/HEPES buffer without phosphate [containing in mM: 
HEPES, 10 (pH 7.4); NaCl, 118; CaCl2, 1.3; KCl, 4.3; MgSO4, 1.17; NaHCO3, 
4.17; glucose, 11.7] and incubated in this buffer containing 100μCi/mL 
[32P]orthophosphate for 1h at 37°C and 5% CO2. Cells were then stimulated 
with ghrelin (100nM, 5min) and immediately lysed by addition of lysis buffer 
[containing in mM: Tris/HCl, 20 (pH 7.4); NaCl, 150; and EDTA, 3; and 
supplemented with 1% (v/v) Nonidet P-40, and 0.5% (w/v) sodium 
deoxycholate] supplemented with phosphatase and protease inhibitors. 
GHSR1a was then immunoprecipitated from the cleared lysates using GFP-
trap (Chromotek; DE) following manufacturer’s instructions. The washed 
immunoprecipitates were separated by SDS-PAGE on two 10% gels. The first 
gel was dried, and radioactive bands were revealed using autoradiography 
film. The second gel was transferred to nitrocellulose membrane as loading 
control. The analysis of the bands was carried out using ImageJ software 
(National Institutes of Health, Bethesda, MD, US). 
 In the same way, to check the effect of the knock down GRK2 gene 
expression in the 32P incorporation of the mutants, 200,000 cells/well of 
GHSR1a-HA, GHSR1a-HA DM, GHSR1a-HA TM or GHSR1a-HA Total cell lines 
stably expressing GRK2 KO CRISPR/Cas9 plasmid, were plated in 6-well dishes 
24h before experimentation and serum starved over night. The next day, 
cells were washed three times with Krebs/HEPES buffer without phosphate 
and incubated in this buffer containing 100μCi/mL [32P] orthophosphate for 
1h at 37°C and 5% CO2 before being stimulated for 5min with ghrelin 100nM. 
The cells where immediately lysed with lysis buffer supplemented with 
phosphatase and protease inhibitors. Using HA beads from Sigma Aldrich 
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(MO, US) and following manufacturer’s instructions, GHSR1a was then 
immunoprecipitated from the cleared lysates. The washed 
immunoprecipitates were separated by SDS-PAGE on two 10% gels. One of 
the gels was dried, and radioactive bands were revealed using 
autoradiography film while the second gel was transferred to nitrocellulose 
membrane as loading control. The bands analysis was carried out using 
ImageJ software (National Institutes of Health, Bethesda, MD, US). 
 
2.8 GHSR1a receptor purification and Mass Spectrometry 
To purify the GHSR1a, the steps followed were: 
1. Ten confluent T175 flasks of stably GHSR1a-EGFP cells were 
harvested, resuspended in Krebs/HEPES buffer and stimulated with 
ghrelin 100nM at 37°C for 5min. 
2. Membranes were separated and solubilized by addition of 5 mL of 
TE buffer [containing in mM: Tris/HCl, 10 (pH 8.0); and EDTA, 1] plus 
a mixture of protease and phosphatase inhibitors.  
3. After centrifugation at 20,000×g, the resulting supernatant was 
diluted 1:1 with phosphate buffered saline (PBS), and the receptor 
was then purified with GFP-trap (Chromotek, DE) following 
manufacturer’s instructions. 
4. The inmmunoprecipitates were extensive washed with solubilization 
buffer containing 0.5% Nonidet P-40 and the resin was resuspended 
in 2×SDS-PAGE before resolve the samples by SDS-PAGE on 10% gel. 
5. Gel was stained with colloidal Coomassie Blue and the GHSR1a 
receptor was excised from the polyacrylamide. 
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6. Gel pieces were washed three times for 5min with 50mM 
ammonium bicarbonate [(NH4)HCO3].  
7. Reduction and alkylation of cysteines were performed by addition of 
10mM dithiothreitol (DTT) in 50mM (NH4)HCO3 at 55°C for 30min 
followed by addition of 100mM iodoacetamide in 50mM (NH4)HCO3 
for 30min in the dark.  
8. Gel slices were washed three times for 5min with 50mM (NH4)HCO3 
containing 50% acetonitrile and incubated over night at 37°C in 
50mM (NH4)HCO3 containing 10% (v/v) acetonitrile and 1μg of 
sequencing grade trypsin (Promega, Southampton, UK).  
9. After tryptic digestion, phosphopeptides were enriched using PHOS-
SelectTM iron affinity resin.  
LC-MS/MS was carried out then on each sample using an LTQ OrbiTrap mass 
spectrometer (Applied Biosystems, Warrington, UK). Peptides resulting from 
in-gel digestion were loaded at a high flow rate onto a reverse-phase 
trapping column (0.3mm inner diameter × 1mm), containing 5μM of C18 300 
Å Acclaim PepMap media (Dionex, UK) and eluted through a reverse-phase 
capillary column (75μm inner diameter × 150mm) containing Symmetry C18 
100 Å media (Waters) that was self-packed using a high pressure packing 
device (Proxeon Biosystems, Odense, DK). The output from the column was 
sprayed directly into the nanospray ion source of an LTQ Orbital mass 
spectrometer. The resulting spectra were searched against the 
UniProtKB/SwissProt data base using MASCOT software (Matrix Science Ltd.) 
with peptide tolerance set to 5ppm and the MS/MS tolerance was set to 
0.6Da. Fixed modifications were set as carbamidomethyl cysteine with 
variable modifications of phosphoserine, phosphothreonine, 
phosphotyrosine, and oxidized methionine. The enzyme was set to 
trypsin/proline, and up to two missed cleavages were allowed. Peptides with 
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a Mascot score greater than 20 and where the probability (p) that the 
observed match was a random event was <0.05 were included in the 
analysis. In Mascot, the ions score for an MS/MS match is -10Log(p), based 
on the calculated probability, p, that the observed match between the 
experimental data and the database sequence is a random event. The 
spectra of peptides reported as being phosphorylated were interrogated 
manually to confirm the precise sites of phosphorylation. 
 
2.9 GHSR1a/β-arrestin interaction assays: BRET 
 A bioluminescence resonance energy transfer (BRET) assay was used 
to monitor interactions between GHSR1a mutants and β-arrestins. HEK293 
cells were co-transfected with eYFP tagged-GHSR1a-WT (eYFP-GHSR1a-WT), 
eYFP-GHSR1a-DM, eYFP-GHSR1a-TM or eYFP-GHSR1a-Total plasmids and 
Rluc-β-arrestin 1 or Rluc-β-arrestin 2 at a ratio of 4:1 or the ratio indicated in 
the graph, using Lipofectamine 2000 (Life Technologies, Invitrogen; NY, US) 
and following manufacturer’s indications. After 24h incubation, cells were 
subcultured into poly-D-lysine-coated white 96-well microplates, incubated 
for a further 24h prior to the assay and serum starved over night. Cells were 
then washed with Hanks' balanced salt solution (Gibco, CA, US) and 
incubated in this buffer for 30min prior to conducting the assay. To initiate 
the assay, the Rluc substrate coelenterazine (Life Technologies, Invitrogen; 
NY, US) was added to a final concentration of 2.5μM and incubated for 
10min at 37°C. Following a further 5min incubation with ghrelin, 
luminescence emissions at 535nm and 475nm were measured using a 
CLARIOstar (BMG Labtech; Offenburg, DE), and the BRET signal was 
presented as the 535/475 ratio multiplied by 1000 to yield the arbitrary milli-
BRET units.  
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2.10 Confocal assays 
 For analysis of the endocytosis time course, HEK293 cells on poly-D-
lysine-coated coverslips were transfected with the EGFP-tagged GHSR1a-WT, 
GHSR1a-DM, GHSR1a-TM or GHSR1a-Total. The cells were serum starved 
overnight in a humidified atmosphere of 95% air and 5% CO2 at 37°C prior to 
conduct the assay. To prevent de novo protein synthesis, the cells were 
preincubated for 2h at 37°C with 90μM cycloheximide. The cells were then 
preincubated for 30 min at 4°C in ice-cold Earle’s buffer [containing (in mM): 
140 NaCl, 5 KCl, 1.8 CaCl2, and 3.6 MgCl2 (pH 7.4); and, complemented with 
0.2% BSA, 0.01% glucose, 90μM cycloheximide, and 0.8mm of 1–10 
phenanthrolene] in the presence/absence of ghrelin (100nM). Internalization 
was promoted at the indicated time by placing the cells at 37°C. After rinsing 
the cells three times at 4°C with ice-cold Earle’s buffer, they were fixed for 
10min with 4% paraformaldehyde dissolved in 0.1mM PBS (pH 7.4). Before 
the coverslips were mounted using Vectashield medium with DAPI (Vector 
Laboratories, Compiègne, FR), the cells were rinsed again in cold Earle’s 
buffer. To determine the interaction between the GHSR1a and β-arrestins, 
the HEK293 cells were cotransfected with the EGFP-tagged GHSR1a-WT, 
GHSR1a-DM, GHSR1a-TM or GHSR1a-Total and the corresponding RFP-
tagged β-arrestin 1 or m-cherry-tagged β-arrestin 2 in a 1:1 ratio. To analyze 
the effect of ghrelin truncates in the endocytosis time course, HEK293 cells 
stably expressing GHSR1a-EGFP were stimulated with ghrelin or the 
corresponding ghrelin truncate (100nM).  
 For immunofluorescence analysis of ERK1/2 activation, the HEK293 
cells were transfected and cultured as indicated above. After ghrelin 
stimulation for the indicated times, the cells were fixed with 4% buffered 
paraformaldehyde-PBS for 15min and washed with PBS three times. The cells 
where then permeabilized with PBST (1% (v/v) Tween 20 PBS) supplemented 
with 1% (v/v) Triton X-100 for 30min, blocked with PBST containing 1% (v/v) 
Triton X-100, 5% (v/v) heat-inactivated normal goat serum, and 0.2% (w/v) 
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BSA for 60min and incubated with anti-pERK1/2(T202/Y204) antibody diluted 
in PBST (1:500) over night at 4°C. After three washes with PBS, cells were 
incubated with the secondary antibody (Alexa Fluor 594-conjugate goat anti-
rabbit antibody) in PBST (1:1000) for 60min at room temperature. 
Vectashield medium with DAPI (Vector Laboratories, Compiègne, FR) was 
used to mountain the coverslips.  
 Digital images of cells were acquired with a Leica TCS-SP5 spectral 
confocal microscope (Leica Microsystems; Heidelberg, DE). 
 
2.11 Small interfering RNA (siRNA) silencing of gene expression 
Chemically synthesized double-stranded siRNA duplexes for GRKs, β-arrestin 
1,  β-arrestin 2 and PKCα were selected from ON-TARGET plus SMART pool 
siRNA from Thermo Fisher Scientific (Dharmacon, Lafayette, CO, US). 
Mouse β-arrestin 1 (5′→3′): ACGGGAAGCUCAAGCAUGA; 
UCAUAGAGCUUGACACCAA;GGAGAACCCAUCAGCGUUA; 
UGGAUAAGGAGAUCUAUUA. 
Human β-arrestin 1 (5′→3′): UGGAUAAGGAGAUCUAUUA, 
AUGGAAAGCUCACCGUCUA,GAACUGCCCUUCACCCUAA, 
GAACGAGACGCCAGUAGAU. 
Mouse β-arrestin 2 (5′→3′): GUGCCAAAACAAUAGAAGA, 
AUACCAACCUCAUCGAAUU,CUACUUGAAGGACCGGAAA, 
GGGCCUGUCUUUCCGCAAA. 
Human β-arrestin 2 (5′→3′): CGAACAAGAUGACCAGGUA, 
CGGCGUAGACUUUGAGAUU,GGGCUUGUCCUUCCGCAAA, 
UAGAUCACCUGGACAAAGU. 
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Human PKCα (5′→3′): UAAGGAACCACAAGCAGUA, 
UUAUAGGGAUCUGAAGUUA,GAAGGGUUCUCGUAUGUCA
, UCACUGCUCUAUGGACUUA 
Human GRK2 (5′→3′): GGGACGUGUUCCAGAAAUU, 
GCUCGCAUCCCUUCUCGAA,GGAAUCAAGUUACUGGACA, 
GCGAUAAGUUCACACGGUU 
Human GRK3 (5′→3′): GGUACCUAUGAACCUAGAA, 
CCAGAAUGGAAUUUAAAGA,CUGUGUAUAUUGACUUUCA, 
CUGCAUCCUGUCCUUGAUA 
Human GRK5 (5′→3′): GAGAACCAUUCCACGAAUA, 
GAACGUGUUUGGACCUAAU, GGUGAACAUUGCAAUAGAA 
Human GRK6 (5′→3′): CGAACACGGUGCUACUCAA, 
GAAAGUGAACAGUAGGUUU,GAGCUUGGCCUACGCCUAU, 
GGUAGAGAAUGAACGGUAC 
Human PDK1 (5′→3′): CGAGGAGACAGAAACUGAA, 
GAGCUGUGUUGUUAGUUA,GUAGAGUUUGUAUGUUUGA 
An ON-TARGET plus Non-targeting siRNA was used as a control for all siRNA 
experiments. The cells were transfected with Lipofectamine 2000 (Life 
Technologies, Invitrogen, NY, US) according to the manufacturer’s 
instructions. Based on the short half-life of these siRNAs during adipocyte 
differentiation (~4 days), the confluent 3T3-L1 cells were transfected after 
the induction of adipogenesis with 0.5mM IBMX, 25μM DEX, and 861nM 
ghrelin in DMEM containing 10% (v/v) FBS for 3 days, and then after siRNA 
transfection maintenance in DMEM containing 10% (v/v) FBS supplemented 
with 172nM ghrelin for 3 days to finalize the differentiation. 
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2.12 Phosphoprotein gel stain 
 HEK293 cells stably expressing GHSR1a-EGFP were transfected with 
GRK2, GRK3, GRK5 and GRK6 SiRNA as indicated above. The cells where then 
immediately lysed with lysis buffer supplemented with phosphatase and 
protease inhibitors. After 18,000xg centrifugation, GHSR1a was 
immunoprecipitated from the cleared lysates using GFP-Trap (Chromotek; 
DE). The washed immunoprecipitates were separated by SDS-PAGE on two 
10% gels. The first polyacrylamide gel was stained with Pro-Q Diamond 
phosphoprotein stain and the second one was stained with SYPRO Ruby 
protein gel stain as a control. Both labeling solutions were purchased from 
Life technologies, Invitrogen (NY, US). 
For Pro Q staining the protocol followed was: 
1. Gel fixation. The gel was immersed in 100mL of fix solution (50% 
methanol, 10% acetic acid) and incubated at room temperature with 
gentle agitation 30min. The fixation step was repeated to ensure 
that all of the SDS was washed out of the gel and leaved it over 
night. 
2. Gel washing. The gel was washed three times in 100mL of ultrapure 
water with gentle agitation for 10min each time.  
3. Gel Staining. The gel was incubated in 60mL of Pro-Q® Diamond 
phosphoprotein gel stain with gentle agitation in the dark for 90min.  
4. Gel Destaining. The gel was incubated in 100mL of destain solution 
with gentle agitation for 30min at room temperature, protected 
from light. This procedure was repeated two more times.  
5. Gel washing. The gel was washed three times with 100mL of 
ultrapure water at room temperature for 5min per wash. 
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For Sypro Ruby staining the protocol was: 
1. Gel fixation. The gel was immersed in 100mL of fix solution (50% 
methanol, 7% acetic acid) and agitated on an orbital shaker for 
30min. The fixation step was repeated one more time. 
2. Gel washing.  The gel was washed three times in 100mL of ultrapure 
water with gentle agitation for 10min each time.  
3. Gel staining. The gel was incubated in 60mL of Pro-Q® Diamond 
phosphoprotein gel stain with gentle agitation over night.  
4. Gel washing. The gel was washed in 100mL of wash solution (10% 
methanol, 7% acetic acid) for 30min. The gel was then rinsed in 
100mL of ultrapure water twice for 5min each wash. 
All the images were obtained scanning the gels with a Typhoon fluorescence 
scanner (GE, Uppsala, SE). 
 
2.13 Immunoblot analysis 
 Serum-starved cells were stimulated with ghrelin or the 
corresponding ghrelin truncate for the indicated time period at 37°C and 5% 
CO2. The medium was then aspirated and the cells were lysed with the lysis 
buffer described before supplemented with protease and phosphatase 
inhibitors. The solubilized lysates were transferred into centrifuge tubes and 
left at 4°C for 15min, before pre-cleared it by centrifugation at 18,000×g for 
15min at 4°C. Protein concentration was evaluated with the QuantiPro BCA 
assay kit from Sigma-Aldrich (MO, US). Subsamples (same amount of protein) 
of each sample were separated by SDS-PAGE on 10% gels and transferred to 
nitrocellulose membranes. The immunoreactive bands were detected by 
enhanced chemiluminescence (Pierce ECL Western Blotting Substrate; 
Thermo Fisher Scientific, Pierce, Rockford, IL, US). The resulting protein 
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bands were scanned and analyzed using ImageJ software (National Institutes 
of Health, Bethesda, MD, US) and normalized for the corresponding loading 
controls.  
In assays where HEK293 cells stably expressing GHSR1a-EGFP where 
pretreated with inhibitors, the concentrations and times employed were: 
1. Pertussis toxin (PTX) from Gibco (CA, US), 100ng/ml 12h. 
2. Wortmannin from Santa Cruz Biotechnology (CA, US), 1µM 30min. 
3. Gö6850 (Bisindolylmeleimide I) from Santa Cruz Biotechnology (CA, 
US), 100nM 30 min. 
4. Gö6983 [2-[1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl]-3-(1H-
indol-3-yl) maleimide] from Santa Cruz Biotechnology (CA, US), 
100nM 30min. 
5. Gö6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-
5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] from Santa Cruz 
Biotechnology (CA, US), 100nM 30min. 
 
2.14 Proliferation assays 
 Cell proliferation of HEK293 expressing the GHSR1a-WT or the 
correspondent mutant was determined using the bromodesoxiuridina (BrdU) 
incorporation-ELISA assay (Roche, Swiss) following manufacturer’s 
instructions. Briefly, 10,000 cells/well were plated in 96-well microplates and 
cultured in DMEM supplemented with ghrelin (100nM) or FBS 10% (v/v) as a 
positive control for 12h and then were incubated with 10mg/mL BrdU for 
another 12h before being fixed with FixDenat solution. The fixed cells were 
further treated with anti-BrdU-POD working solution, and rinsed with 
washing solution before substrate solution was added. The absorbance at 
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370nm (reference wavelength at 492nm) was measured using an ELISA plate 
reader (Reader VersaMaxPLUS). To measure the effect of the ghrelin 
truncates in HEK293 stably expressing GHSR1a-EGFP cell proliferation the 
cells were stimulated with 100nM ghrelin or the corresponding ghrelin 
truncate. 
 
2.15 Quantification of lipid accumulation 
 Differentiated 3T3-L1 adipocytes were fixed for at least 2h with 4% 
buffered paraformaldehyde-PBS. Each well was rinsed three times with Milli-
Q water and was incubated 5min at room temperature with 60% iso-
propanol. Lipid droplets were then stained for 10min at room temperature 
with a working solution of 60% (v/v) Oil Red O. For quantification, cells were 
washed extensively with water to remove unbound dye, iso-propanol was 
added to the stained culture plates and the colour was analyzed by 
spectrophotometry at 520nm. 
 
2.16 Inositol 1-phosphate accumulation 
 Inositol 1-phosphate (IP1) accumulation was measured using IP-One 
HTRF® assay kit (Cisbio Assays, MA, US) based on FRET technology. GHSR1a-
WT, GHSR1a-DM, GHSR1a-TM or GHSR1a-Total cell lines tagged with EGFP 
were cultured into poly-D-lysine-coated 96-well microplates, incubated for a 
further 24h prior to the assay and serum starved over night.  
For IP-One HTRF® kit the protocol followed was: 
1. Cells were then treated with stimulation buffer containing LiCl which 
inhibit IP1 degradation plus ghrelin 100nM during 1h at 37°C.  
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2. Cells where lysed by addition of lysis buffer for 30min at room 
temperature with shaking at 500rpm.  
3. To initiate the assay, 16μL of lysate was transferred to a white 384-
well plate and incubated with IP1-d2 conjugate 30min at 37°C. 
4. Anti-IP1 conjugated with Tb-cryptate was added during 1h at room 
temperature with shaking at 500rpm. This antibody competes with 
native IP1 produced by cells and IP1 coupled to the dye d2. 
5. Fluorescence emissions were measured at 665nm and 620nm using 
a CLARIOstar (BMG Labtech; Offenburg, DE) and IP1 acummulation 
was determined from the ratio 665nm/620nm. 
 
2.17 GH assay  
 To measure murine GH secretion, GC-GHSR1a cells were plated in 6-
well dishes 24h prior to induce the secretion during 30min with ghrelin or 
the corresponding truncate (100nM) diluted in fresh DMEM phenol red free. 
The medium collected from the stimulated GC-GHSR1a cells culture and the 
non-stimulated control was concentrated to 100µL by ultracentrifugation 
using Amicon Ultra 3kDa tubes (Millipore, Billerica, US) and following 
manufacturer’s indications. The amount of total protein of each sample was 
then evaluated with the QuantiPro BCA assay kit from Sigma-Aldrich (MO, 
US). Equal amount of protein was loaded on each well of the microtiter plate 
coated by a pre-tittered amount of anti-Growth Hormone polyclonal 
antibodies of the rat/mouse GH ELISA kit from EMD Millipore (Billerica, 
Massachusetts, US). After incubation with the primary antibody, the 
unbound materials from samples were washed and the second biotinylated 
anti-Growth Hormone polyclonal antibody was added. Following three 
washes, the horseradish peroxidase conjugate was loaded before wash the 
plate again. The quantification of immobilized antibody-enzyme conjugates 
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was monitored following the horseradish peroxidase activity in the presence 
of the substrate 3,3’,5,5’-tetramethylbenzidine. The enzyme activity was 
measured spectrophotometrically by the increased absorbency at 450nm, 
corrected from the absorbency at 590nm, after acidification of formed 
products. Since the increase in absorbency is directly proportional to the 
amount of captured rat or mouse Growth Hormone in the unknown sample, 
the latter can be derived by interpolation from a reference curve generated 
in the same assay with reference standards of known concentrations of Rat 
GH.To evaluate the effect of β-arrestins, before being stimulated with ghrelin 
100nM GC-GHSR1a cells were transfected 48h prior to conduct the assay 
with the corresponding SiRNA. GH levels were analyzed in quadruplicate. 
 
2.18 Data analysis 
All values are presented as mean ± standard error of the mean (SEM). 
Student t test were performed to assess the statistical significance of 2-way 
analysis. For multiple comparisons, ANOVA was employed. p<0.05 was 











































Identification of phosphorylation sites in GHSR1a  
  The GHSR1a following 5min stimulation with ghrelin (100nM) 
enhanced its phosphorylation ∼2.8±0.2 fold compared to the unstimulated 
receptor as monitored by increased incorporation of 32P after 
immunoprecipitate the GHSR1a into a protein with an apparent molecular 
mass ∼100KDa (Figure 11).  
   
Figure 11. 32P incorporation of GHSR1a. HEK293 cells transiently expressing 
C-terminally EGFP-tagged GHSR1a were treated with the agonist ghrelin (100 
nM) or vehicle for 5min and then labeled with 32P. Left panel, autoradiogram 
and loading control (EGFP immunoblot) is shown. Right panel, levels of 32P 
were quantified by densitometry, normalized to GHSR1a-EGFP, and 
expressed as fold increase relative to the control cells. Immunoblot is 
representative of five independent experiments. The data are expressed as 
the mean ± SEM (*, p < 0.05). 
 
 To identify the precise phosphorylation sites, upon 5min of 
stimulation with ghrelin (100nM), the receptor was excised from a stained 
polyacrylamide gel to generate tryptic peptides which was analyzed by mass 
spectrometry-based proteomics (Figure 12 and 12’). The study of the spectra 
generated, revealed 3 serines (S349, S362 and S363) and 2 threonines (T350 and 
T366) as phosphor-acceptor sites at the C-tail of the GHSR1a. Despite the 
tryptic peptides generated from the receptor revealed peptide coverage of 
the third intracellular loop, there was no detection of phosphorylation 






Figure 12. Mass spectrometry identification of phosphorylation sites in the 
GHSR1a. HEK293 cells transiently expressing C-terminally EGFP-tagged 
GHSR1a were immunoprecipitate and then digest for analysis using mass 
spectrometry. A and B, representative mass spectra and associated 
fragmentation tables that cover the four phosphorylated residues identified 
in various experiments, 2 serines (S349, and S363) and 2 threonines (T350 and 




Figure 12’. Mass spectrometry identification of phosphorylation sites in the 
GHSR1a (Continuance). A, representative mass spectra and associated 
fragmentation table that cover the phosphorylated residues S362 and T366 
identified in different experiments (in green are noted the EGFP amino 
acids). D, Summary of the mass spectrometry data. 
 
 To ensure that these amino acids are the key residues in GHSR1a 
phosphorylation, recombinant HEK cells were generated in which these 
phosphor-acceptor sites were mutated to A residues that are not able to be 
phosphorylated (Figure 3A). In a double mutant of GHSR1a, designated 
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GHSR1a-DM, in which T350 and S349 were mutated to A, phosphorylation in 
response to 5min of treatment with ghrelin was reduced by 57±3% (Figure 
13B). Triple mutation of GHSR1a, designated GHSR1a-TM, in which S362, 
S363and T366 were mutated to A, phosphorylation was decreased by 58±2%. A 
further variant was generated where all of the residues identified by mass 
spectrometry to be phosphorylated were substituted by A (S349, S362, S363, T350 
and T366) in a mutant, designated GHSR1a-Total. The phosphorylation status 
of GHSR1a-Total was significantly less than that of either GHSR1a-DM or 
GHSR1a-TM indicating that the sites of ghrelin-regulated phosphorylation in 




Figure 13. Analysis of GHSR1a mutations. A, Illustration of the S and T (red) 
phosphorylation sites that were mutated to A in the GHSR1a-WT C-tail to 
generate the GHSR1a-DM, GHSR1a-TM and GHSR1a-Total mutants. B, Upper 
panel, 32P labeling of HEK293 cells expressing either the EGFP-tagged 
GHSR1a-WT or the mutants. Bottom panel, levels of 32P were quantified by 
densitometry, normalized to GHSR1a-EGFP, and expressed as fold increase 
relative to the control cells expressing the GHSR1a-WT. Immunoblot is 
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representative of five independent experiments. The data are expressed as 
the mean ± SEM (*,# p < 0.05).  
β-arrestin 1 and 2 recruitment are related to the phosphorylation of 
the GHSR1a C-tail.  
 To determine the importance of the GHSR1a C-terminus 
phosphorylation in directing specific signaling events, the receptor 
endocytosis induced by ghrelin (100nM) was studied by confocal microscopy 
in HEK293 cells expressing GHSR1a-WT or mutants tagged with EGFP.  In the 
resting cells, the fluorescence associated with the receptor was 
predominantly localised to the plasma membrane. Despite being treated 
with cycloheximide to inhibit the de novo protein synthesis, the cells had also 
shown a slight fluorescent associated with the Golgi apparatus. After 
exposure to ghrelin for 20 and 60min, the GHSR1a-WT-associated 
fluorescence almost completely disappeared from the plasma membrane to 
be redistributed to a population of intracellular vesicles distributed 
throughout the cytoplasm (Figure 14A). In cells transfected with the GHSR1a-
DM, the receptor was primarily spread throughout the cytoplasm after 20 
and 60min of agonist treatment although the population of intracellular 
vesicles was relatively reduced compared with the WT receptor (Figure 14A). 
By contrast, ghrelin was not able to induce receptor internalization in 
HEK293 cells expressing GHSR1a-TM or GHSR1a-Total, consequently, the 
fluorescence associated to the receptor remained to be mainly localized in 
the plasma membrane and no redistribution of the fluorescent could be 









Figure 14. Analysis of the endocytosis time course by confocal microscopy 
of the EGFP-tagged GHSR1a-WT and the mutants. HEK293 cells transiently 
transfected were stimulated with ghrelin (100nM) for different times at 37°C. 
Confocal images are representative of three independent experiments. 
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 In order to resolve whether this change in the patterns of 
endocytosis displayed by the mutant receptors was due to differences in 
their ability to interact with β-arrestins, cells were transiently co-transfected 
with the receptors tagged with EGFP and RFP-tagged β-arrestin 1 or m-
cherry-tagged β-arrestin 2. As shown in Figures 15A and 15B, the receptors 
(shown in green) were located at the cell surface, whereas RFP-β-arrestin 1 
or m-cherry-β-arrestin 2 was uniformly distributed in the cytoplasm in 
unstimulated cells (shown in red). After 20min of ghrelin (100nM) treatment, 
GHSR1a-WT appeared to colocalize with both β-arrestin 1 and 2 in endocytic 
vesicles (shown in yellow; Figure 5A and B). This colocalization reflected the 
assembly of a protein complex containing β-arrestin and the receptor being 
more robust at 60min of agonist stimulation. Similarly, ghrelin stimulation of 
GHSR1a-DM triggered the colocalization of the receptor with both β-
arrestins at 20 and 60min (Figure 15A and 15B). However, this colocalization 
was rather evenly distributed in the cytoplasm in a diffuse granular pattern, 
with no apparent enhanced localization in endocytic vesicles. By contrast, in 
the case of GHSR1a-TM and GHSR1a-Total no colocalization events was 
observed, the green fluorescence associated to the receptors were seen at 
plasma membrane while the red fluorescence of the β-arrestin continued 
distributed throughout the cytoplasm after agonist treatment (Figure 15A 





Figure 15. Phosphor-acceptor sites in GHSR1a-WT C-tail govern binding and 
trafficking patterns of β-arrestins. A, Trafficking of RFP-β-arrestin 1 and 
EGFP-tagged GHSR1a-WT or mutants in HEK293. B, Trafficking of m-cherry-β-
arrestin 2 and EGFP-tagged GHSR1a-WT or mutants in HEK293. A and B, 
Confocal images are representative of three experiments. Colocalization of β-
arrestins (red) and receptors (green) is pointed by yellow arrows. 
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 The contributions of agonist dependent phosphorylation in the C-tail 
of GHSR1a to recruitment of β-arrestin 1 and 2 were further studied by BRET 
assays, which measured the capacity of association between eYFP-tagged 
GHSR1a or mutants with and Rluc-β-arrestin 1 or 2 in real time in HEK293 
living cells (Figure 16A and 16B, respectively). These BRET assays revealed 
that the β-arrestins are recruited by GHSR1a in a ghrelin dependent manner. 
The concentration response curves of β-arrestin 1 for the double mutant 
receptor in comparison with the WT had shown a slight but significant 
decrease in both potency (pEC50= 7.54 for GHSR1a-WT, and pEC50= 7.10 for 
GHSR1a-DM; p<0.05) and efficacy (81.3% of GHSR1a-WT response; p<0.05).  
At the same time, β-arrestin 2 response curves had also exhibited that 
GHSR1a-DM significant decrease in both potency (pEC50= 7.30 for GHSR1a-
WT, and pEC50= 7.14 for GHSR1a-DM; p<0.05) and efficacy (82.4% of 
GHSR1a-WT response; p<0.05) compared with the GHSR1a-WT. The fact that 
the BRET values for β-arrestin 2 recruitment were higher than those for β-
arrestin 1 in both receptors, GHSR1a-WT and GHSR1a-DM, might be caused 
by a conformational difference in the configuration of the receptor/β-
arrestin complex that results in a greater distance between the luciferase 
and eYFP tags or by a distinct affinity for β-arrestin 1 and 2. On the other 
hand, in comparison with the WT receptor, the triple and the total mutants 
exhibited a significant reduction in the efficacy to recruit β-arrestin 1 (36.8% 
and 31.8% of GHSR1a-WT, respectively) and β-arrestin 2 (24.6% and 18.0% of 
GHSR1a-WT, respectively) what is consistent with the lack of receptor/β-









Figure 16. BRET approach to monitor the β-arrestin interactions with the 
GHSR1a. A, BRET ratio was estimated in response to incremental doses of 
ghrelin for the interactions between the YFP-GHSR1a-WT/GHSR1a mutants 
and Rluc-β-arrestin 1. B, BRET ratio was estimated in response to 
incremental doses of ghrelin for the interactions between the YFP-GHSR1a-
WT/GHSR1a mutants and Rluc-β-arrestin 2. 
 
An intriguing observation was that the potency and efficacy of β-arrestins 
binding was subtly reduced by the mutation of T350 and S349 in the GHSR1a-
DM, which might suggest the implication of these phosphorylation sites in 
the fine-tune of their interactions with the GHSR1a. To gain further insight 
into this possibility, the BRET values of different acceptor/donor ratios was 
monitored (eYFP-receptor/Rluc-β-arrestin) to determine at which acceptor-
donor ratio are observed the maximal BRET (BRETmax) and the half-maximal 
BRET (BRET50) for each β-arrestin (β-arrestin 1 Figure 17A and β-arrestin 2 
Figure 17B). BRET50 values for GHSR1a-DM/β-arrestins interactions were 
higher than those for GHSR1a-WT, which advocate that the WT receptor has 
a higher relative affinity for both β-arrestins than the double mutant. 
However, the BRETmax values were smaller for the GHSR1a-DM, which 
suggests that the nature of the receptor/β-arrestin interactions were 
different for both receptors; in such a way that the acceptor and donor tags 






Figure 17. BRET curve acceptor/donor for WT and DM GHSR1a and β-
arrestins A, Cells were transfected with a constant amount of β-arrestin 1 
and increasing amounts of YFP-GHSR1a-WT or YFP-GHSR1a-DM (acceptors) 
and treated with ghrelin. Net BRET is graphed as a function of 
acceptor/donor. B, Titration curves monitoring net BRET in response to 
varying acceptor/donor ratios were performed as in A for β-arrestin 2. BRET50 
and BRETmax values calculated from three independent experiments. 
 
 All these results taken together indicate that the binding of β-
arrestins with the phosphorylated C-tail of the GHSR1a involves two separate 
areas of interaction. The first interplay zone comprises the phosphorylation 
sites S362, S363and T366 that serve as essential phosphate recognition elements 
for the β-arrestin recruitment, and the second area contains the 
phosphorylation residues T350 and S349 that might stabilize active 
conformation of β-arrestins.  
 
β-arrestin signaling is determined by the phosphorylation of the C-
tail of the GHSR1a: ERK1/2 and Akt activation.  
 To determine the role of the two areas of phosphorylation founded 
in the GHSR1a C-tail (S362, S363and T366, or S349 and T350) the phosphorylation 
of ERK1/2 [pERK1/2(T202/Y204)] induced by ghrelin was analyzed in HEK293 
114 Results 
 
cells transiently transfected with GHSR1a-WT, GHSR1a-DM, GHSR1a-TM or 
GHSR1a-Total. In GHSR1a-WT cells stimulated with ghrelin (100nM), 
pERK1/2(T202/Y204) was resolved into two components, mediated 
respectively, by G proteins or β-arrestins signalling, as was previously 
described81. Here the same was observed for the WT receptor,  while the G 
protein-dependent activity was quick with a maximum peaking within ∼5min, the β-arrestins-dependent ERK1/2 activation was slower in onset 
with a maximum peak ∼20min, but sustained over time (Figure 18A). 
However, this sustained pERK1/2(T202/Y204) signal declined with C-terminal 
tail mutations GHSR1a-DM, GHSR1a-TM, and GHSR1a-Total keeping only the 
fast and transient G protein-dependent activation. The decrease in the 
ERK1/2 activation is consistent with the decline of the receptor to form 
complex with β-arrestins and subsequently act trough them (Figure 18A). 
Intriguingly, GHSR1a-Total had shown a slightly higher sustained ERK1/2 
activation than the GHSR1a-TM despite had been exhibited less interaction 
with β-arrestins. To further study the role of the mutations in the sustained 
ERK1/2 activation we used MEF cells from wild-type mice (MEF WT), MEF 
cells from β-arrestin1 null mice (β-arrestin 1-/-) and MEF cells from β-arrestin 
2 null mice (β-arrestin 2-/-). In the MEF WT cells, ghrelin led to the same 
pattern observed in HEK293 cells, where the GHSR1a-Total had shown higher 
sustained ERK1/2 activation than the GHSR1a-TM and even a little higher at 
20min than the GHSR1a-DM (Figure 8B). In the MEF β-arrestin 2-/- cells, there 
were no differences in the kinetic of the ERK1/2 activation among GHSR1a-
WT, GHSR1a-DM, GHSR1a-TM and GHSR1a-Total in which the G protein-
dependent pathway is the major mechanism (Figure 18D). Nonetheless, in 
the MEF β-arrestin 1-/- the GHSR1a-Total had shown again a higher sustained 
ERK1/2 activation at 20min than the other receptors, suggesting that the lack 
of internalization allows the total mutant remain available to be activated by 
ghrelin in the plasma membrane indefinitely (Figure 18C). To clarify this 
hypothesis, a re-stimulation assay was performed with the GHSR1a-WT and 
the GHSR1a-Total mutant (Figure 18E). As was described in previous studies, 
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the maximum peak of internalization of the GHSR1a-WT is between 20 and 
60min; moreover, after 2h of ghrelin treatment the GHSR1a starts to 
reappear in the membrane and the recycling is almost 100% after 3h96. For 
this reason, the ERK1/2 activation produced by the receptor WT and the total 
mutant was compared after re-stimulate with ghrelin 5min cells that was 
previously stimulated for 1h and 2h. While the phosphorylation of ERK1/2 at 
5 and 65min was similar for both receptors, at 125min the phosphorylation 
induced by the total mutant was clearly higher, suggesting that the GHSR1a-









Figure 18. GHSR1a and mutants ERK1/2 activation. A-D, MEF WT, β-arrestin 
1-/-, β-arrestin 2-/- and HEK293 cells were transiently transfected with the 
indicated GHSR1a-WT or mutants and stimulated with ghrelin (100nM) for 
the indicated times. E, HEK293 cells were transiently transfected with the 
GHSR1a-WT or GHSR1a-Total, treated with ghrelin (100nM) for the indicated 
times and re-stimulated for 5min. A-E, The levels of pERK1/2(T202/Y204) 
were quantified by densitometry, normalized to total ERK1/2, and expressed 
as the fold change relative to the unstimulated cells. Results are 
representative of three independent experiments. The data are expressed as 




 Going a step forward, to study the functional consequence of 
ERK1/2 activation associated to the C-terminal phosphor-acceptor sites of 
the GHSR1a, was determined the mitogenic activity associated to the 
GHSR1a mutants in HEK293 cells. Whereas the GHSR1a-WT cells treated with 
ghrelin 100nM incorporated BrdU at a ∼2-fold over control, cells expressing 
GHSR1a-DM or GHSR1a-TM failed to incorporate BrdU and GHSR1a-Total 
exhibit a negligible incorporation (Figure 19A). The results obtained with the 
GHSR1a-TM suggest that ghrelin-induced proliferation is not dependent on 
the G protein mediated signaling. However, the lack of GHSR1a-DM 
mitogenic effect might be related to the spatial control over MAPKs that 
exerts the stabilization of the active conformation of β-arrestins. Accordingly, 
the subcellular location of pERK1/2(T202/Y204) was examined in HEK293 
cells transfected with EGFP tagged GHSR1a-WT and GHSR1a-DM receptors 
upon ghrelin stimulation (100nM) by confocal microscopy. While, in cells 
expressing the double mutant, pERK1/2(T202/Y204) was mainly located in 
the cytoplasm after activation, in the cells expressing the WT receptor, 
pERK1/2(T202/Y204) was principally translocated into the nucleus (Figure 
19B). As a result, the phosphor-acceptor residues located in the GHSR1a C-




Figure 19. Functional relation between the GHSR1a-associated β-arrestin-
scaffolded complex and the ERK1/2 activity. A, Mitogenic effect of ghrelin 
(100nM) on cells transiently transfected with the GHSR1a-WT or mutants 
(n=6). Results were expressed as a-fold of the BrdU incorporation relative to 
control cells. Results are representative of three independent experiments. 
The data are expressed as the mean ± SEM (*,# p < 0.05). B, The HEK293 cells 
expressing GHSR1a-WT and GHSR1a-DM and stimulated with ghrelin for 
indicated time were stained for pERK1/2(T202/Y204) and images were taken 
by confocal microscopy. DAPI was used to identify nuclei. Confocal images 




 The role of the five phosphor-acceptor residues founded on the 
GHSR1a was also study in the ghrelin-induced Akt activation. The model for 
the activation of Akt by ghrelin similarly to ERK1/2 activation, involves the 
interplay of an early Gi/o protein-dependent pathway and a late pathway 
mediated by β-arrestins82,98. In fact, the GHSR1a-WT transiently transfected 
in HEK293 cells had shown after stimulation with ghrelin (100nM) a 
pAkt(S473) activation resolved into two components: a first G protein-
dependent signaling with maximum activity at ∼10 min, and a second part 
mediated by β-arrestins activation which was sustained over time (Figure 
20A). This sustained pAkt(S473) signal decreased with C-tail mutations of 
GHSR1a-DM and GHSR1a-TM, reflecting the decline of the receptor/β-
arrestin signaling complex formation, an effect confirmed in MEF WT , MEF 
β-arrestin 1-/- and 2-/- cells (Figure 20B-D). Notwithstanding, the GHSR1a-
Total mutant had shown an Akt activation sustained in time comparable to 
that of GHSR1a-WT in HEK293, MEF WT and both β-arrestin knock out MEFs. 
According to what was observed in the activation of ERK1/2, the effect of the 
ghrelin re-stimulation on Akt phosphorylation (S473) was also studied (Figure 
20E). While the phosphorylation of Akt at 5min was similar for both 
receptors, at 65min the activation induced by the total mutant is nearly 
double than that of WT and at 125min the phosphorylation induced by the 
total mutant is double than the control while GHSR1a-WT hardly induces Akt 
activation. All of these seem to confirm the idea of the GHSR1a-Total being 
reactivated by ghrelin due to its capacity of remain on the plasma membrane 









Figure 20. GHSR1a and mutants Akt activation. A-D, MEF WT, β-arrestin 1-/-, 
β-arrestin 2-/- and HEK293 cells were transiently transfected with the 
indicated GHSR1a-WT or mutants and stimulated with ghrelin (100nM) for 
the indicated times. E, HEK293 cells were transiently transfected with the 
GHSR1a-WT or GHSR1a-Total, stimulated with ghrelin (100nM) for the 
indicated times and re-stimulated for 5min. A-E, The levels of pAkt(S473) 
were quantified by densitometry, normalized to total ERK1/2, and expressed 
as the fold change relative to the un-stimulated cells., Results are 
representative of three independent experiments. The data are expressed as 




 To determine the importance of the GHSR1a C-tail in directing 
specific Akt signaling events, the effects of β-arrestins depletion by siRNA 
were examined on the intracellular lipid storage in 3T3-L1 cells mediated by 
ghrelin. This approach was necessary because both undifferentiated 
(preadipocytes) and differentiated 3T3-L1 (adipocytes) express GHSR1a 
endogenously, making it difficult discern the differences among GHSR1a 
mutants. Thus, using a standard adipogenic induction cocktail of IBMX, DEX 
and ghrelin, 3T3-L1 preadipocyte cells were induced to differentiate into 
adipocytes for 72h (early differentiation), followed by inhibition of β-arrestin 
1 and 2 with specific siRNAs during terminal differentiation. At day 6 after 
the initiation of differentiation, Oil Red O staining was performed to monitor 
the intracellular lipid accumulation induced by ghrelin. Efficiency of β-
arrestin 1 and 2 siRNA depletion was confirmed by immunoblot analysis after 
differentiation (65±5% and 69±2%, respectively). The depletion of β-arrestin 
1 or 2 produced a substantial inhibition of the ghrelin-induced fat droplet 
storage in comparison to siRNA control (61±13% and 73±16%, respectively; 
Figure 21), which confirms that the β-arrestin signal complex determines the 
adipogenic functions of ghrelin and subsequently the importance of the 
phosphor-acceptor sites of the GHSR1a C-tail in the regulation of the 








Figure 21. GHSR1a-mediated lipid accumulation associated to β-arrestin-
scaffolded complex. Effect of siRNA depletion of β-arrestins on 3T3-L1 cells 
terminal adipogenesis. After the induction for 3 days under treatment with 
IBMX (0.5mM), DEX (25μM), and ghrelin (861nM) in DMEM/10% FBS, the 
cells were transfected with β-arrestin 1 or 2 siRNAs and then maintained for 
3 days with ghrelin (172nM) in DMEM/10% FBS. The cells were stained with 
Oil red O and the lipid droplet accumulation were analyzed using the 
spectrophotometric absorbance at 520 nm. The results are expressed as the 
fold change of lipid accumulation relative to the differentiation control.  
 
Gq/11 activity of ghrelin is not related to the phosphorylation of the 
C-tail of the GHSR1a. 
 Upon activation, GHSR1a carries information within the cell via a 
transient increase of intracellular Ca2+ through the generation of inositol 
1,4,5-triphosphate (IP3) triggered by protein subunit Gαq/1181. Because the 
lifetime of IP3 is extremely short, Gαq/11-dependent GHSR1a activation can be 
followed by monitoring IP3 degradation products, such as inositol 1-
phosphate (IP1), which accumulates in the cell in the presence of lithium 
chloride. The study of the IP1 accumulation in response to ghrelin (100nM) 
performed in HEK293 cells transiently expressing GHSR1a-WT, GHSR1a-DM, 
GHSR1a-TM and GHSR1a-Total had revealed similar values among all the 
receptors (Figure 22A). On the other hand, it is also well established that 
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GHSR1a is able to stimulate GH release through intracellular Ca2+ 
concentration via IP3. To further investigate the role of the GHSR1a 
phosphorylation sites and β-arrestin signaling, the effect siRNA knockdown 
of β-arrestins on the GH release in GC cells was tested. As with 3T3-L1 cells, 
this approach was was selected based on the stable GHSR1a expression in GC 
cells. The transfection of the cells with β-arrestin 1 or 2 siRNAs decreased the 
β-arrestin 1 and 2 expression by 50±1% and 80±3% respectively, but did not 
alter significantly the GH release induced by ghrelin in comparison to that in 
cells treated with control siRNA (Figure 22B). These results taken together 
demonstrate the independent contribution of G proteins and β-arrestins 
mediated pathways in the GHSR1a signaling. Thus, the GHSR1a display the 
capacity to tip the scale of functional selectivity in either direction: toward 






Figure 22. The functionality of Gq/11-protein mediated GHSR1a signaling is 
independent of receptor phosphorylation and β-arrestins binding. A, 
Determination of ghrelin-induced IP1 accumulation in HEK293 cells 
transiently transfected with the GHSR1a-WT or mutants. The levels of IP1 
were expressed as the fold change relative to the unstimulated GHSR1a-WT 
cells. Data points correspond to means ± SEM of three experiments 
performed in triplicate. B, Left panel, The levels of β-arrestins and actin were 
quantified by densitometry, normalized to total actin, and expressed as fold 
relative to the siRNA control. Immunoblots are representative of three 
independent experiments. The data are expressed as the mean ± SEM (*, p< 
0.05). Right panel, Analysis of the effect of ghrelin (100 nM) on the GH 
release in GC-GHSR1a cells in the absence or presence of β-arrestin siRNAs. 
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Ghrelin induces PKCs activation through Gi/o and G q/11-dependent 
mechanism 
 Protein kinase C (PKC) is a family of protein kinase enzymes 
that are involved in controlling the function of other proteins through the 
phosphorylation of hydroxyl groups of S and T amino acid residues. The 
PKC family is divided into three subfamilies, based on their second 
messenger requirements: conventional (or classical), novel, and 
atypical170. Conventional (c)PKCs contain the isoforms α, β, and γ. These 
PKCs depends on Ca2+, diacylglycerol (DAG), and phospholipid such as 
phosphatidylserine for activation. Novel (n)PKCs include the δ, ε, η, and θ 
isoforms, and require DAG, but do not need Ca2+ for activation. Thus, 
conventional and novel PKCs are activated through the same signal 
transduction pathway as phospholipase C. On the other hand, atypical 
(a)PKCs (including protein kinase ζ and ι / λ isoforms) require neither Ca2+ 
nor DAG for activation170. Previous studies from our group demonstrated 
the activation of cPKC such as PKCα/β in the system ghrelin/GHSR1a81 . 
To explore the activation of the rest of the PKCs induced by ghrelin 
through GHSR1a, the phosphorylation of the cPKC, PKCγ [pPKCγ (T514)]; 
the nPKCs, PKCε [pPKCε(S729)], PKCδ[pPKCδ(T507)], PKCη [pPKCη(T655)], 
PKCθ [pPKCθ(T538)]; and, the aPKC, PKCµ/PKD [pPKCµ(S916)], and PKCζ 
[pPKCζ(T410)], was evaluated in HEK293 cells stably expressing GHSR1a 
(HEK-GHSR1a). Maximum of pPKCε(S729) was observed at 5-10min post 
ghrelin stimulation (100nM). pPKCδ(T507), pPKCµ/PKD(S916), 
pPKCη(T655) and pPKCζ(T410) showed maximal phosphorylation at 10-
20min of ghrelin activation, whereas pPKCθ(T538) increased during all 
the tested time. By contrast, PKCγ was not activated by ghrelin (Figure 
23). 
                                                                
170 Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and 





Figure 23. PKCs activation upon ghrelin stimulation. HEK-GHSR1a cells 
were stimulated with ghrelin (100nM) at the indicated times. The levels 
of pPKCγ(T514), pPKCε(S729), pPKCδ(T507), pPKCη(T655), pPKCθ(T538), 
pPKCµ(S916) and pPKCζ(T410), were quantified by densitometry, 
normalized to actin, and expressed as the fold change relative to the 
unstimulated cells. Immunoblots are representative of three independent 
experiments and the data are expressed as the mean ± SEM. 
 
 Because several signaling pathways are able to activate PKCs and 
these pathways are related to the action of G proteins, we first analyzed 
the implication of Gi/o by PTX pretreatment (100ng/ml, 12h), which 
selectively inhibits the coupling of Gi/o to the receptor. As shown in Figure 
24A, ghrelin-induced activation of PKCδ, PKCθ, PKCµ and PKCζ was 
inhibited by PTX action. By contrast, PKCη phosphorylation was not 
affected by PTX. Moreover, the phosphoinositide-3-kinase (PI3K) is one of 
the intracellular targets of Gi/o protein, which was described to be 
involved in the activation of PKCε81. For this reason, the effect of 
wortmannin, PI3K inhibitor was examined in the activation patterns of 
PKCs. After wortmanin pretreatment (1µM, 30min), PKCδ, PKCθ, PKCµ 
and PKCζ activation was abolished while PKCη activation was not affected 
(Figure 24B). Furthermore, the Gi/o/PI3K downstream signaling produces 
PIP3 and consequently allows the translocation to the membrane of 
phosphoinositide-dependent kinase-1 (PDK1), which triggers Akt 
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phosphorylation at T308 being involved in the activation of Src through 
PKCε signaling98. The cell transfection of PDK1 siRNA (∼80% reduction 
related to siRNA control; Figure 24C) attenuated PKCδ, PKCθ, PKCµ, and 
PKCζ activation induced by ghrelin (100nM) whereas PKCη 
phosphorylation was not affected by PDK1 siRNA. Thus, the 












Figure 24. PKCs activation through Gi/o/PI3K route. A, HEK-GHSR1a cells 
were treated with PTX 100ng/ml 12h and stimulated 5min with ghrelin 
100nM. B, HEK-GHSR1a cells were treated with wortmannin 1µM 30min 
and stimulated with ghrelin 100nM 5min. A and B, Levels of pPKCδ(T507), 
pPKCη(T655), pPKCθ(T538), pPKCµ(S916) , and pPKCζ(T410) were 
quantified and normalized to actin. C, HEK-GHSR1a cells were transfected 
with PDK1 or control siRNA and treated with ghrelin 100nM 5min. The 
levels of PDK1 and actin were quantified, normalized to actin, and 
expressed as fold relative to the siRNA control. The levels of 
pPKD1(S241), pPKCδ(T507), pPKCη(T655), pPKCθ(T538), pPKCµ(S916) 
,pPKCζ(T410), were quantified by densitometry and normalized to actin. 
A-C, Immunoblots are representative of three independent experiments. 
The data are expressed as the mean of the fold change relative to the 
unstimulated cells ± SEM (*, p < 0.05). 
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To study if PKCη is acting trough Gq/11/PKCα pathway, the effect of PKCα 
knockdown by siRNA was explored. PKCα depletion by siRNA transfection 
caused a ∼52% reduction and produced a similar attenuation of PKCη 
activation (∼53%) (Figure 25). In addition, the phosphorylation of PKCµ 
was unaffected by PKCα knockdown. Human PKCµ was firstly catalogued 
as a PKC but deeper studies made it the founding member of a new 
family of S/T kinases known as protein kinase D (PKD) family and changed 
its name by PKD or PKD1171. It is believed that PKD is a direct substrate of 




Figure 25. PKCs activation through Gq/11 route. HEK-GHSR1a cells were 
transfected with PKCα or control siRNA and treated with ghrelin 100nM 
5min. The levels of PKCα and actin were quantified by densitometry, 
normalized to total ERK1/2, and expressed as fold relative to the siRNA 
control. The levels of pPKCα(T638/641), pPKCη(T655), and pPKCµ(S916), 
were quantified by densitometry and normalized to ERK1/2. 
Immunoblots are representative of three independent experiments. The 
data are expressed as the mean of the fold change relative to the 
unstimulated cells ± SEM (*, p < 0.05). 
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 To deeper analyze whose PKCs are activating PKD under ghrelin 
stimulation (100nM) several PCKs inhibitors were used. As would be 
expected, Gö6850, which inhibits all PKCs, reduced PKD phosphorylation. 
On the contrary, Gö6976, inhibitor of cPKCs (α/β and γ), did not 
attenuate PKD phosphorylation.  Finally, treatment with Gö6983, 
inhibitor of cPKCs (α, β, and γ) and nPKCs (ε, δ, η and θ), decreased PKD 
activation but in lesser extent than Gö6850, suggesting that PKD is 
activated by atypical PKCs. Taken together all the results, PKCη activation 
is dependent on the activation of Gq/11/PKCα pathway whereas PKD is 




Figure 26. PKD activation mediated by PKCs. HEK-GHSR1a cells were 
treated with Gö6850, Gö6983 or Gö6976 100nM 30min and 5min with 
ghrelin (100nM). The levels of PKCα and actin were quantified by 
densitometry, normalized to total actin, and expressed as fold relative to 
the siRNA control. The levels of pPKCα(T638/641), pPKCη(T655), and 
pPKCµ(S916), were quantified by densitometry and normalized to actin. 
Immunoblots are representative of three independent experiments. The 
data are expressed as the mean of the fold change relative to the 
unstimulated cells ± SEM (*, p < 0.05). 
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β-arrestin binding to the phosphorylated GHSR1a form is 
mediated by PKCα/GRK2-dependent pathway 
 G protein-coupled receptor kinases (GRKs) play an important 
role in the desensitization of G protein-mediated signalling of GPCRs. GRK 
phosphorylation of the receptors leads to the subsequent binding of β-
arrestins, which partially quenches receptor coupling to G proteins172. 
Each of the GRKs can potentially phosphorylate different S and T residues 
on a given receptor, and the phosphorylation pattern can be biased by 
the receptor conformation established by bound ligand. The diversity of 
the barcoding to flexible β-arrestin explains the multidimensional nature 
of signalling in the GPCR superfamily.  GRKs share certain characteristics 
but are distinct enzymes with specific regulatory properties. GRK2, 3, 5 
and 6 are ubiquitously expressed in mammalian tissues, whereas GRK1, 4 
and 7 are confined to specific organs. GRK1 and 7 are expressed in retinal 
rods and cones, respectively, and GRK4 is present in testis, cerebellum 
and kidney92,173. Transfection of GRK siRNAs into HEK-GHSR1a cells 
reduced expression of the targeted GRK compared to either non-silencing 
or control siRNA-transfected cells. Besides, all siRNAs demonstrated 
marked isoform specificity depleting GRK levels by 60-80% (Figure 27A). 
The ability of GRKs to support ghrelin-induced phosphorylation of 
GHSR1a was estimated in cells transfected with siRNAs targeting the 
GRKs. Stimulation with ghrelin (100nM) for 5min led to prominent 
phosphorylation of the receptor, which was significantly reduced in cells 
transfected with GRK2 or GRK6 siRNAs (Figure 27B). After transfection 
with GRK3, or 5 siRNAs, no effect in receptor phosphorylation was 
observed upon ghrelin stimulation (100nM) (Figure 27B). 
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Figure 27. Analysis of GRKs implication on GHSR1a phosphorylation. A, 
HEK-GHSR1a cells were transfected with GRK2, 3, 5, 6 or control siRNA 
and treated with ghrelin 100nM 5min. The levels of GRKs and GAPDH 
were acquired by densitometry as silencing control. Immunoblots are 
representative of three independent experiments. B, Left panel, ProQ 
staining of phosphoproteins was performed in the same HEK293 cells 
transfected with GRK2, 3, 5, 6 or control siRNA. Right panel, levels of 
phosphorylation were quantified by densitometry, normalized to Sypro 
signal, and expressed as fold increase relative to the SiRNA control cells. 
Immunoblot is representative of three independent experiments. The 
data are expressed as the mean ± SEM (*,# p < 0.05).  
 
Next, the effect of CRISPR suppression of GRK2 expression was further 
examined on ghrelin-promoted phosphorylation in HEK293 cells 
expressing GHSR1a-WT or mutants tagged with HA. Phosphorylation of 
GHSR1a-WT or GHSR1a-DM was significantly reduced in cells transfected 
with GRK2-CRISPR transfected cells compared to GRK2 control cells. On 
the contrary, GHSR1a-TM cells were not affected by GRK2 KO-CRISPR 
transfection (Figure 28). This result suggests the implication of GRK2 in 
the phosphorylation of the S362, S363and T366 residues. 




Figure 28. Detailed analysis of GRK2 implication on GHSR1a 
phosphorylation. A, HEK293 cells stably expressing the GHSR1a tagged 
with HA in the presence or not of the GRK2 KO CRISPR/Cas9 plasmid were 
used as control of GRK2 inhibition. Immunoblot is representative of three 
independent experiments. The data are expressed as the mean ± SEM (*,# 
p < 0.05). B, Upper panel, 32P labeling of HEK293 cells stably expressing 
the GHSR1a or its mutants tagged with HA in the presence or not of the 
GRK2 KO CRISPR/Cas9 plasmid. Bottom panel, levels of 32P were 
quantified by densitometry, normalized to GHSR1a-HA, and expressed as 
fold increase relative to the control cells expressing the GHSR1a-WT. 
Immunoblot is representative of three independent experiments. The 
data are expressed as the mean ± SEM (*,# p < 0.05) 
 
 To test the role of GRK2 in GHSR1a ghrelin-mediated signaling, 
the effect of CRISPR-mediated GRK2 depletion (∼80%, Figure 29A) was 
measured on ERK1/2 and Akt activation. In ghrelin-stimulated HEK-
GHSR1a control cells, ERK1/2 activation reached maximal levels rapidly 
and remained stable for up to 10-20min (Figure 29A). By contrast, ghrelin 
stimulation (100nM) of GRK2 KO-CRISPR-transfected cells caused a rapid 
and transient ERK activation compared to control cells and the loss of the 
persistent phase of the signal, previously shown to be β-arrestins-
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mediated. Similarly, after depletion of GRK2 the rapid and transient Akt 
activation was observed, whereas β-arrestin-dependent persistent phase 
was missed (Figure 29B). Taken together, these results suggest that GRK2 
empower β-arrestins-mediated signaling to ERK1/2 and Akt. 
 
 
Figure 29. GRK2 effect on ERK1/2 and Akt activation. HEK-GHSR1a cells 
were transiently transfected with GRK2 KO CRISPR/Cas9 plasmid and 
stimulated with ghrelin (100nM) for the indicated times. A, Effect of GRK2 
KO CRISPR depletion. Levels of GRK2 were quantified by densitometry 
and normalized to GAPDH B, The levels of pERK1/2(T202/Y204) were 
quantified by densitometry and normalized to total ERK1/2. Results are 
expressed as the fold change relative to the unstimulated cells C, The 
levels of pAkt(S473) were quantified by densitometry and normalized to 
total Akt. Results are expressed as the fold change relative to the 
unstimulated cells A-C, Immunoblots are representative of three 
independent experiments. The data are expressed as the mean ± SEM. 
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 Previous studies described that β-arrestins signaling is 
dependent on the Gq and Gi/o protein activation81,82, which advocates that 
certain key components of the G protein-dependent routes are required 
to determine β-arrestins recruitment and signaling. This prompted us to 
speculate about the implication of GRK2 and/or second messenger 
kinases like PKCs as the missing link between G proteins and β-arrestins. 
Firstly, was tested whether Gi/o protein inactivation by PTX alters GRK2 
signaling from GHSR1a. Upon ghrelin stimulation of control cells, GRK2 
phosphorylation at S670 reached maximal levels rapidly and decreased 
for up to 10min very slowly (Figure 30B). By contrast, in PTX-treated cells, 
ghrelin action caused a similar kinetic pattern with the persistent phase 
lost. As would be expected, PKCα activation was not affected by PTX 
treatment as it is dependent of Gq. After inactivation of Gi/o, only very 
rapid and transient ERK1/2 activation was observed (Figure 30C). 
Moreover, Gi/o inactivation caused a similar kinetic pattern of Akt 
activation, but with elevated levels of S473 phosphorylation, compared to 
control cells (Figure 30D). These results ruled out the implication of Gi/o -
dependent signaling and pointed the implication of Gq-dependent 
signaling on the early GRK2 phosphorylation.  
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Figure 30. Gi/o-dependent signaling. HEK-GHSR1a cells were treated with 
PTX 100ng/ml 12h and stimulated with ghrelin (100nM) the indicated 
times. A, The levels of pPKCα (T638/641), were quantified and normalized 
to total PKCα. B, The levels of pGRK2 (S670) were quantified and 
normalized to total GRK2. C, The levels of pERK1/2(T202/Y204) were 
quantified and normalized to total ERK1/2. D, The levels of pAkt(S473) 
were quantified and normalized to total Akt. A-D, Immunoblots are 
representative of three independent experiments. The data are 
expressed as the mean of the fold change relative to the unstimulated 
cells ± SEM (*, p < 0.05).  
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 On the other hand, GRK2 has also been shown to be substrate 
for PKCs174,175. Considering the ghrelin-induced-PKC activation, it is 
possible to speculate about the role of PKCα/β and/or PKCε as GRK2 
phosphorylation mediators. However, the PKCε dependence of Gi/o-
protein activation ruled out this PKC and pointed directly to PKCα/β as 
upstream target for GRK2 phosphorylation. Indeed, PKCα depletion by 
siRNA transfection (∼70%; Figure 31A) caused a decreased in ghrelin-
induced GRK2 S670 phosphorylation (Figure 31B). Furthermore, after 
inhibition of PKCα, only very rapid and transient ERK1/2 and Akt 
activation was observed under ghrelin stimulation (100nM) (Figure 31C 
and 31D).  
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Figure 31. PKCα mediated GRK2 phosphorylation and associated ERK1/2 
and Akt activity. A, HEK-GHSR1a cells were transfected with PKCα SiRNA 
and stimulated with ghrelin (100nM) the indicated times. The levels of 
PKCα were quantified by densitometry, normalized to total actin, and 
expressed as fold relative to the siRNA control. B, The levels of 
pGRK2(S670), were quantified and normalized to total GRK2. C, The levels 
of pERK1/2(T202/Y204), were quantified and normalized to total ERK1/2. 
D, The levels of pAkt (S473) were quantified by densitometry and 
normalized to total Akt.  A-D, Immunoblots are representative of three 
independent experiments. The data are expressed as the mean of the 
fold change relative to the unstimulated cells ± SEM (*, p < 0.05). 
 
CHAPTER 3 




Effect of ghrelin truncations in GHSR1a signaling 
 To determine the key structural elements of ghrelin which ensure its 
bioactivity, three different ghrelin truncations was used to evaluate the 
GHSR1a  signaling: COOH-GSS(n-octanoyl)FL-NH2 (1-5 ghrelin), COOH-GSS-(n-
octanoyl)-FLSPEHQRVQQ-NH2 (1-14 ghrelin) and, COOH-GSS-(n-octanoyl)-
FLSPEHQRVQQRKES-NH2 (1-18 ghrelin) (Figure 1A). First, the capacity to 
phosphorylate GHSR1a was tested by 32P incorporation under ghrelin or 
truncates stimulation (100nM, 5min) in HEK-GHSR1a cells. The radiactive 
labeling of the immunoprecipitate receptor showed that 1-5 ghrelin induced 
phosphorylation level comparable to that of ghrelin, while 1-14 and 1-18 
ghrelin showed significant decrease on its ability to phosphorylate GHSR1a 
(∼60% and ∼37% reduction of ghrelin signal, respectively; Figure 32B). 
 
Figure 32. Ghrelin truncates phosphorylation. A, Illustration of the ghrelin 
truncations. B, Left panel, HEK-GHSR1a cells were stimulated 5min with ghrelin 
or the corresponding truncate (100nM) and 32P labeled. Right panel, levels of 
32P were quantified by densitometry, normalized to GHSR1a-EGFP, and 
expressed as fold increase relative to the control cells unstimulated. 
Immunoblot is representative of three independent experiments. The data are 
expressed as the mean ± SEM (*,# p < 0.05).  
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 Following, the effect of ghrelin truncates on receptor endocytosis was 
examined. Internalization of GHSR1a tagged with EGFP was analyzed 20 and 
60min after agonist treatment. Consistent with previous results, the 
fluorescence associated with the GHSR1a in the resting cells, was 
predominantly localised to the plasma membrane while exposure to ghrelin 
for 20 and 60min caused the redistribution of this fluorescence into a 
population of intracellular vesicles spread throughout the cytoplasm (Figure 
33A). In the case of 1-5 ghrelin, at 20min intracellular vesicles were shown 
disseminated all over the cytoplasm although part of the fluorescence 
associated with the GHSR1a remained in the plasma membrane of the cells 
suggesting a reduction in GHSR1a-EGFP internalization. At longer times of 
stimulation (60min) with 1-5 ghrelin, the extent of receptor internalization 
increased although the fluorescence associated to the plasma membrane 
persisted (Figure 33B). Stimulation with 1-14 ghrelin exhibited a diffuse 
distribution of fluorescence in the cytoplasm but close to plasma membrane at 
20min. The diffuse distribution was maintained at longer times of stimulation 
(60min) but with reduction in the number of intracellular vesicles compared to 
ghrelin (Figure 33C). Internalization of GHSR1a induced by 1-18 ghrelin also 
showed a cytoplasmic diffuse distribution of the GHSR1a-associated 
fluorescence at 20min. However, the extent of intracellular vesicles increased 





Figure 33. Endocytosis time course of the EGFP-tagged GHSR1a mediated by 
ghrelin truncates. HEK-GHSR1a cells after stimulation with ghrelin or the 
corresponding truncate (100nM) for different times at 37°C were analyzed by 





 Going a step forward, the effect of ghrelin truncates on ERK1/2 and 
Akt signaling from the activated GHSR1a was tested (Figure 34). 1-5 ghrelin 
stimulation (100 nM) caused a similar kinetic pattern of ERK1/2 activation than 
stimulation with ghrelin (100nM), but with elevated levels of activation of 
ERK1/2. A slow rate of Akt activation compared to control ghrelin was 
observed maintaining the transient and persistent phases (Figure 34). 
Stimulation with 1-14 ghrelin (100nM) showed to modify the rapid and 
transient ERK1/2 activation. This effect was more pronounced in Akt in which 
the transient Akt activation was lost. By contrast, 1-18 ghrelin (100nM) caused 
a similar kinetic pattern of ERK1/2 and Akt activation, but with decreased 
levels compared to ghrelin (Figure 34).  
 
Figure 34. Ghrelin truncates action on ERK1/2 and Akt activation. The HEK-
GHSR1a cells were stimulated with ghrelin or the corresponding truncate (100 
nM) for the indicated times. A, The levels of pERK1/2(T202/Y204) were 
quantified by densitometry,  normalized to total ERK1/2, and expressed as the 
fold change relative to the unstimulated cells. B, The levels of pAkt(S473) were 
quantified by densitometry,  normalized to total Akt, and expressed as the fold 
change relative to the un-stimulated cells. A and B, Immunoblots are 
representative of three independent experiments. The data are expressed as 




 To further examine the action of ghrelin truncates on GHSR1a-
associated signaling, the mitogenic and adipogenic outcome was measured by 
BrdU incorporation and Oil red staining respectively. Figure 35A shows that the 
proliferative effect after 1-5 ghrelin stimulation (100nM) was similar to that 
observed in ghrelin-stimulated HEK-GHSR1a cells. By contrast, the mitogenic 
capacity associated to GHSR1a was significantly reduced when cells where 
stimulated with 1-14 or 1-18 ghrelin (100nM). However, similar effect on lipid 
droplet accumulation during adipogenesis was shown for all the ghrelin 




Figure 35. Functional consequences of ghrelin truncates-mediated activation 
of ERK1/2 and Akt. A, Mitogenic effect of ghrelin or the corresponding 
truncate (100nM) on HEK-GHSR1a (n=6). Results were expressed as a-fold of 
the BrdU incorporation relative to control cells. The data are expressed as the 
mean ± SEM (*,# p < 0.05). B, Effect of ghrelin or the corresponding truncate 
(100nM) on terminal adipogenesis in 3T3-L1 cells. The cells were stained with 
Oil red O and the lipid droplet accumulation were analyzed using the 
spectrophotometric absorbance at 520 nm. The results are expressed as the 
fold change of lipid accumulation relative to the differentiation control. 
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 Finally, was also tested the consequences of stimulation with ghrelin 
truncates on GHSR1a-induced GH secretion in GC-GHSR1a cells by ELISA. 
Stimulation with 1-14 or 1-18 ghrelin (100nM) enhanced the GH secretion to 
similar levels than those of ghrelin, while the activation with 1-5 ghrelin 
(100nM) failed to induce GH secretion (Figure 36). 
   
Figure 36. GH secretion mediated by ghrelin truncates. Analysis of the effect 
of ghrelin or the corresponding truncate (100nM) on the GH release in GC-
GHSR1a cells. Data are from three independent experiments and were 
performed in quadruplicate. The data are expressed as mean of a-fold over 













CHAPTER 1. GHSR1a phosphorylation. 
 The interplay of the classic G protein-mediated signaling and β-
arrestin-dependent pathways largely determines the cellular consequences 
of the GHSR1a activation. One of the most important post-translational 
modifications mediated by agonist stimulation is the phosphorylation of the 
GPCRs. The covalent modifications produced on the receptor mediates its 
desensitization as well as provides a mechanism by which receptors can 
engage with β-arrestins and trigger specific downstream signaling 
pathways83,84. However, until now the phosphorylation status of the GHSR1a 
remained to be elucidated.     
 The map of the specific phosphorylation sites of the GHSR1a 
obtained by mass spectrometry-based proteomic approach allowed the 
elucidation of the functional capabilities imparted by these specific 
phosphorylation events on the β-arrestin signaling. While the phosphor-
acceptors S362, S363and T366 residues were primarily responsible for β-arrestin 
1 and 2 binding, receptor internalization and β-arrestin-induced ERK1/2 and 
Akt activation, the T350 and S349 sites stabilized the interaction between the 
GHSR1a and β-arrestins, and as a whole contributed to desensitization. These 
results are consistent with a model in which the phosphor-acceptor residues 
of the GHSR1a C-tail are able to lead to distinct patterns of phosphorylation 
and consequently induce different β-arrestins interactions and determine the 
ultimate cellular consequences of β-arrestins-induced pathways91,92. The 
obtained data support the hypothesis of receptor phosphorylation barcode, 
whereby the distinct pattern of phosphorylation triggers defined 
downstream signaling and are further consistent with the concept that the C-
terminal phosphorylation pattern establishes the subtle differences in β-
arrestins conformation that expose distinct sets of binding partner sites 




 The failure to bind β-arrestins and internalize exhibited by the 
GHSR1a when the S362, S363 and T366 residues were deleted (GHSR1a-TM and 
GHSR1a-Total), corroborates the classic model for GPCR signaling which 
predicts that receptor phosphorylation at multiple intracellular S and T 
positions creates binding sites for β-arrestins. By contrast, deletion of T350 
and S349 of the GHSR1a C terminus (GHSR1a-DM) demonstrated β-arrestins 
recruitment and receptor internalization, ruling out any implication for 
switching-in the β-arrestins binding. These results suggest that the most 
terminal phosphor-acceptor sites S362, S363 and T366 of the GHSR1a confer 
crucial high-affinity binding for β-arrestins recruitment and also facilitate 
receptor internalization coordinating protein-protein interactions. This 
finding supports the notion of a bulk negative charge on the C-tail 
responsible for driving receptor/β-arrestins interactions. Despite the 
phosphorylation of these three sites (S362, S363 and T366) can promote β-
arrestins interaction with the GHSR1a, it is the phosphorylation distal to T350 
and S349 residues that is required to determine the ultimate outcome of 
receptor internalization and β-arrestin signaling. Loss of the phosphorylation 
sites T350 and S349 modified the internalization partner from a typical 
population of intracellular vesicles to redistribution into a diffuse cytoplasmic 
granular pattern. Besides, a deeper study using BRET to closely analyze real-
time interplay of β-arrestins with the GHSR1a-DM, revealed that β-arrestin 1 
and 2 are both recruited to this mutant receptor but with a lower apparent 
affinity, corroborating that while S362, S363 and T366 phosphorylation can 
promote β-arrestins recruitment with the GHSR1a, distal phosphorylation of 
T350 and S349 residues is required to stabilize the receptor/β-arrestins 
interactions. Finally, the fact that GHSR1a-DM had not shown the capacity of 
translocate ERK1/2 to the nucleus and induce cell proliferation, hallmarks of 
β-arrestins-mediated downstream signaling of the GHSR1a, further support 
the observation that β-arrestins action is dependent on the receptor’s 
phosphorylation pattern or ‘barcode’81. Although there are studies indicating 
that differences in β-arrestins signaling are dependent upon the stability of 
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the complex formed176,177,178, it is possible to speculate that differences in 
stability contribute or affect to the binding domains on β-arrestins that are 
exposed, resulting in association of certain putative binding partners and 
exclusion of others91,179,180. Recent studies using a β-arrestins biosensor to 
detect gross changes in conformation suggest phosphorylation of the 
different sets of sites engenders the distinct functionality of β-arrestins by 
inducing different conformations of the receptor-bound β-arrestins91,179. 
These findings are consistent with a model where the patterning of receptor 
phosphorylation sites establishes a code that determines the conformation 
of the bound β-arrestins and, subsequently, its functional capabilities. Thus, 
differences in β-arrestins binding in response to recruitment to GHSR1a 
versus GHSR1a-DM might underlie the differences in signaling we observed. 
 Upon stimulation a GPCR is activated and β-arrestins are mobilized 
from its dimeric or tetrameric storage in its basal conformation. The 
proposed model for the interaction between both involves a biphasic 
mechanism which starts with the connection of the phosphorylated C-tail of 
the receptor and the N-terminal domain of β-arrestins. In the next step, the 
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insertion of the finger loop of β-arrestins within the receptor core brings 
additional binding sites into action consequently inducing additional 
conformational changes to yield a high affinity receptor/ β-arrestins 
complex73,181,182. Following this complex formation, the phosphor-acceptor 
residues further act in agreement with other structural elements of the 
intracellular core of the receptor. Indeed, recent studies have shown that 
P148 and L149 amino acids located in the second intracellular loop of GHSR1a 
generate receptors with a strong bias to G protein and β-arrestins, 
respectively, supporting a role for conformation-dependent signaling bias in 
the wild-type receptor93. Thus, the nature of the active conformation of β-
arrestins and the signaling outcome is determined by the complex ensemble 
of the GHSR1a phosphorylation sites within the C-tail in combination with 
structural elements within intracellular loops that confer the functional 
selectivity. 
 An interesting aspect is the functional selectivity associated to the 
differential GHSR1a-stimulated G protein- and β-arrestin-mediated signaling 
to control particular cellular response. The β-arrestin knockdown results 
revealed that the GH-releasing activity results from G protein signaling with 
no implication of β-arrestin signaling because this action occurs upon 
activation of β-arrestin-impaired GHSR1a. With the mutation of phosphor-
acceptor sites, the proliferative effect of ghrelin was impaired indicating the 
implication of β-arrestins-mediated ERK1/2 pathway. Furthermore, the β-
arrestins-scaffolded complex positively determines Akt activity and adipocyte 
differentiation. The implication of these scaffolding proteins during ghrelin-
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induced adipogenesis in 3T3-L1 cells was previously demonstrated. β-
arrestins determined the adipocyte differentiation and the expression levels 
of master regulators of early, the CCAAT/enhancer-binding protein β 
(C/EBPβ) and the CCAAT/enhancer-binding protein δ (C/EBPδ), and terminal, 
the peroxisome proliferator-activated receptor (PPARγ) and the 
CCAAT/enhancer-binding protein α (C/EBPα), adipogenesis137. Initially, these 
findings imply the existence of independent G protein- and β-arrestins-
mediated pathways. However, this is not the case at all, especially if we take 
into consideration the fact that β-arrestin signaling is dependent on the Gi/0 
protein activation81,82. This fact suggests that certain key components of the 
Gi/0 protein-dependent signaling pathways are required to determine β-
arrestins recruitment and signaling. This prompted us to speculate about the 
implication of GRKs or second messenger kinases, i.e. PKCs, on the receptor 
phosphorylation and consequent β-arrestins binding as the missing link 
between Gi/0 protein and β-arrestins. These data highlight the concept that 
the functions of β-arrestins may be pre-specified by the particulars of the 
GRK/PKC-receptor interaction. This is consistent with previous work on 
multiple different receptors showing a requirement for GRKs-mediated 
receptor to activate specific transducers as well as to affect transducer 
functionality in a selective manner91,183. Thus, the patterning of receptor 
phosphorylation sites, barcode, engenders subtle differences in β-
arrestins/receptor interactions that lead to divergent β-arrestins-dependent 
signaling events. Ultimately, the fact that GHSR1a can direct functionality via 
different pathways unveils a tremendous potential for new approaches in 
developing therapeutics at this receptor particularly taking into account the 
physiological and pathophysiological effects in both neural and peripheral 
tissue.  
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CHAPTER 2. PKCs and GRKs: role in GHSR1a signaling. 
 Originally, PKC were considered to be the mediators of GPCR 
phosphorylation and desensitization184. Despite they seemed to be relegated 
to a secondary action after the discovery of the role of GRKs and β-arrestins 
in GPCR desensitization185,186, these kinases have shown to be crucial in 
GPCRs regulation as second messenger transducers during years187. PKC 
family enzymes regulate the function of other proteins by phosphorylation of 
the hydroxyl groups of S and T residues. Based on their second messenger 
requirements, PKC family is divided into three subfamilies: conventional (α, 
β, and γ isoforms), novel (δ, ε, η, and θ isoforms), and atypical (ζ and ι / λ 
isoforms). These PKC isotypes are unique, not only with respect to primary 
structure, but also on the basis of expression patterns, subcellular 
localization, activation in vitro and responsiveness to extracellular signals 
170,188,189. Upon ghrelin stimulation was observed that GHSR1a was able to 
activate PKC α/β and η through Gq/11 route while PKC ε, δ, θ, µ and ζ were 
activated via Gi/o/PI3K/PKD1 pathway81. More interesting, was the fact that 
PKCµ exhibited the capacity to be a direct substrate of novel and atypical 
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PKCs via Gi/o/PI3K, demonstrating that PKCµ firstly catalogued as a PKC it is 
actually a PKD which acts as a binding partner of PKC and might confer 
specificity to PKC signaling through their direct interaction and consequently 
mediate many receptor transduction pathways190,191. 
 In the particular case of GHSR1a, β-arrestin signaling had shown to 
be dependent on the G-protein activation81,82,98. This fact suggests that 
certain key components of the G protein-dependent signaling pathways are 
required to determine β-arrestin recruitment and signaling. Indeed, previous 
works demonstrated that ghrelin leads to Akt activation through an early 
Gi/o-protein-dependent cascade and a late pathway mediated by β-
arrestins82,98. The starting point is the Gi/o-protein dependent PI3K activation 
promoting the membrane recruitment of Akt, which is phosphorylated at Y 
by c-Src with the subsequent phosphorylation at A-loop (T308) and HM 
(S473) by PDK1 and mTORC2, respectively. Once the receptor is activated, a 
second signaling pathway is mediated by β-arrestins 1 and 2, involving the 
recruitment of at least β-arrestins, c-Src and Akt. This β-arrestin-scaffolded 
complex leads to full activation of Akt. In agreement with these results, 
assays performed in 3T3-L1 preadipocyte cells indicate that β-arrestins and c-
Src are implicated in the activation of Akt in response to ghrelin through the 
GHSR1a82. This result supports the implication of G protein-dependent 
proteins, such as Src activation via Gi/o-protein, prompting β-arrestins-
mediated signaling events, i.e. full activation of Akt. Additionally, the impact 
of GRKs or second messenger kinases like PKCs on the receptor 
phosphorylation and the consequent β-arrestin recruitment might be 
proposed as the missing link between G proteins and β-arrestins. Our data 
highlight the possibility that the functions of β-arrestins may be pre-specified 
by GRK/PKC-receptor interaction. This is consistent with previous work on 
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other receptors that exhibited GRKs requirement to activate specific 
transducers as well as to affect transducer functionality in a selective 
manner91,192. How GRKs are activated by GPCRs is not currently clear; 
however, several studies suggested a link between PKC and GRKs 
activation174,175,193. From the data presented so far, GRK2 and GRK6 are 
critical regulators of GHSR1a phosphorylation. With a focus on GRK2 
activation, the lack of effect of inhibition of Gi/o by PTX treatment ruled out 
the implication of Gi/o-protein dependent activation, and subsequently the 
involvement of PKCs which are activated via Gi/o-protein (PKC ε, δ, θ, µ and 
ζ). Considering the kinetic pattern of PKCs, PKCα/β may have a role in the 
GRK2 activation. Indeed, siRNA silencing of PKCα decreased GRK2 
phosphorylation demonstrating the link between them; moreover, PKCα had 
exhibited before the capacity to activate GRK2 leading to kinase 
action175,193. Intriguingly, using mutational and conformational studies was 
described that PKCα activates GRK2 by phosphorylation of S29175,194; 
however the unavailability of a specific S29 antibody when this work was 
performed lead us to evaluate the phosphorylation of GRK2 at S670. Despite 
S670 is located in the C-terminal domain instead of being in the N-terminal 
domain as S29, both residues are involve in a Gβγ-binding site. While S29 
favor GRK2 interaction with Gβγ subunit with the consequent translocation to 
the plasma membrane and activation, S670 had exhibited the opposite effect 
uncoupling GRK2 and Gβγ subunit195. This GRK2 desensitization by S670 
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phosphorylation was also described as a negative feedback mechanism 
mediated by ERK1/2196. However, assays developed with siRNA directed 
against PKCα inhibited significantly GRK2 phosphorylation at S670 and, 
curiously, β-arrestin-activated EKR1/2 and Akt signaling. These results 
disagree the inhibitory role of S670 phosphorylation by PKCα given that an 
incresed β-arrestin-dependent ERK1/2 and Akt activity should be observed 
under siRNA-mediated knockdown of PKCα. Despite additional studies are 
required to clarify this point, the missing link between G proteins and β-
arrestins seems to be related to Gq/11- and Gi/o-protein-dependent pathways 
through GRKs and Scr signaling. 
 Going a step forward, we also demonstrated the ability of GRK2 and 
6 to phosphorylate the ghrelin receptor. In particular, GRK2 appears to 
phosphorylate specifically the S362, S363and T366 residues of the C-tail of the 
GHSR1a following ghrelin activation. Furthermore, GRK2 had proved to be 
crucial for β-arrestins-mediated signaling to ERK1/2 and Akt at the same time 
that PKCα. Besides, the model by which, GRKs induce functionality in a 
selective manner was demonstrated in other receptors. β2-adrenergic 
receptor, thyrotropin-releasing hormone receptor, angiotensin II receptor 
signaling or V2 vasopressin receptor had shown that receptor 
phosphorylation mediated by GRK2 and GRK3 leaded to receptor 
internalization, while receptor phosphorylation induced by GRK5 and GRK6 
was necessary for β-arrestin-dependent ERK1/2 signaling91,183. These findings 
further support the idea of a GRK-induced phosphorylation barcode at the C-
tail of the GHSR1a that regulates the nature of β-arrestin intracellular 
functions73. The fact that only GRK6 had also exhibited capacity to reduce 
GHSR1a phosphorylation in response to ghrelin and the previous results 
which pointed at the S349, S362, S363, T350 and T366 as the key phosphor-
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acceptor sites of the GHSR1a, lead us to suggest that if GRK2 is responsible 
for the phosphorylation of the distal S362, S363 and T366 sites, GRK6 could be 
mediating the phosphorylation of the proximal S349 and T350 residues and 
subsequently it might be leading the stabilization of the interactions 
between GHSR1a and β-arrestins. Unlike GRK2 and GRK3 which are 
translocated to the plasma membrane where they form a complex with the 
free βγ subunits of heterotrimeric G protein, making its activation dependent 
on G protein α/βγ subunit dissociation, GRK5 and GRK6 are constitutively 
bound to the plasma membrane and thus, can interact with and 
phosphorylate activated receptors independently of heterotrimeric G 
protein197. However, to corroborate that GRK6 is responsible of the 
phosphorylation of the S349 and T350 residues, acting or not through Gi/0 
protein-dependent pathway, and the signaling consequences of this, deeper 
studies are necessary. It is also essential the development of antibodies 
against the phosphorylated forms of GRK6 to follow its activation. 
 Finally, it should be notice that many receptor subtypes like GHSR1a 
are found in more than one tissue type198. Receptors which are expressed in 
different cell types controlling specific cellular responses would be regulated 
in a cell type-specific manner. GPCR phosphorylation is a flexible regulatory 
process that seems to have acceptable diversity and dynamic range to 
accommodate the variety of physiological events triggered by each GPCR 
subtype. Thus, the sites that are phosphorylated in a GPCR might encode the 
signaling properties on the receptor. Phosphorylation mediates regulatory 
features such as β-arrestins recruitment and internalization and 
consequently, cell-type specific phosphorylation may lead to particular 
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signaling functions and a specialized physiological role of the receptor199,200. 
PKCs and GRKs have shown variation in cellular and tissue distribution as well 
as in abundance201,202, which made them the perfect candidates to mediate 
this tissue-dependent phosphorylation code. Thus, the unique 
phosphorylation signature on the receptor might be the result of the specific 
employment of PKCs and GRKs. This could be achieved either by differential 
expression, activation or scaffolding of the kinases. Subsequently, the 
specific array of intracellular second messengers available in each tissue is 
able to determine the activation of one mechanism over another or to 
induce multiple mechanisms simultaneously. For all of this, the final 
physiological function mediated by ghrelin through GHSR1a is dependent on 
the tissue-related PKC and GRK expression. We correlated the specific 
pattern of receptor phosphorylation by GRK2 with the functions of β-
arrestins and propose that the distinct phosphorylation patterns established 
by different GRKs determine a code that imparts the conformations to the 
recruited β-arrestin, thus regulating its functional activities. 
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CHAPTER 3. Determination of active conformations of GHSR1a. 
 Since the discovery of ghrelin in 1999 as the endogenous ligand for 
the GHSR1a, several studies were performed trying to determine the 
minimum structural requirements to induce GHSR1a biological activity. 
Ghrelin is a GH releasing peptide which consists of 28 amino acid residues 
with octanoyl modification at S3. This modification has largely demonstrated 
to be essential for ghrelin activity as GHSR1a recognition of ghrelin is 
dependent of a large hydrophobic group in this specific position7,203,204. The 
importance of this post-translational modification suggests the amino acid 
sequence surrounding the S3 might encode a motif directing the octanoyl 
modification, as the first 10 N-terminal amino acids are identical among the 
different mammalian species. Despite some studies reported that the the 1-5 
truncated form of ghrelin was able to induce intracellular Ca+2 mobilization 
and GH release in vivo7,203 other studies indicated that this truncate form 
lacked the ability of secrete GH in vivo205. To elucidate structural features of 
this peptide necessary for efficient activation of GHSR1a, several short 
peptides derived from ghrelin were tested in receptor phosphorylation, 
endocytosis, early signaling events, proliferation, adipogenesis and GH 
release capacity. The N-terminal part of ghrelin with S(n-octanoyl) in position 
3 was preserved, but the chain was gradually shortened by the omission of 
blocks of several amino acids from the C-terminal end of ghrelin. 
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 Interestingly, a peptide encompassing only the first 5 residues of 
ghrelin, GSS(n-octanoyl)FL-NH2 (1-5 ghrelin), activated the GHSR1a 
phosphorylation as efficiently as ghrelin although the internalization grade 
was somewhat less potent than ghrelin given that the GHSR1a remained 
partially in the membrane instead completely internalize. The differences 
observed in endocytosis could be due to decreased binding affinity to 
GHSR1a205 determining a slow rate of GHSR1a internalization.On the other 
hand, similar activation pattern of ERK1/2 and Akt was observed after 
stimulation with 1-5 ghrelin, being more potent in the G protein-dependent 
ERK1/2 signal and less strong in Akt activation compared to ghrelin. 
Nonetheless, the mitogenic and adipogenic effect was comparable to ghrelin. 
These results prompted us to speculate to a complete activation of β-
arrestin-dependent signaling since proliferative and mitogenic action 
associated to GHSR1a are mediated by β-arrestins which are related to 
receptor phosphorylation. However, 1-5 ghrelin failed to activate GH release 
in GC cells. Considering that GH secretion activity associated to GHSR1a is 
independent on β-arrestin signaling, 1-5 ghrelin shows characteristics of a 
partial agonist for G protein-dependent signaling pathways, activating certain 
G protein-dependent mechanisms. Curiously, 1-5 ghrelin had showed to 
induce intracellular Ca2+ mobilization7, a second messenger involved in GH 
release. This fact supports multiple active conformations of GHSR1a upon 
agonist binding and consequently, the efficacy of GHSR1a is recognized as 
pluridimensional. 
 The peptide comprising the first 14 residues of ghrelin, COOH-GSS-
(n-octanoyl)-FLSPEHQRVQQ-NH2 (1-14 ghrelin), showed a clear decrease in 
the GHSR1a phosphsorylation with different pattern and dynamic of 
endocytosis characterized by smaller vesicles distributed close to the 
membrane. The activation pattern of ERK1/2 was more potent than ghrelin 
signal, leading to an early peak phase of ERK1/2 activation that was 
sustained. According to ERK1/2 pattern, the mitogenic effect was not 
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observed after 1-14 ghrelin stimulation. By contrast, the early peak phase of 
Akt activation was absent showing the sustained plateau phase 
corresponding to β-arrestin signaling. In fact, adipogenic action was 
comparable to ghrelin. There were no differences in the activation of GH 
release. Thus, 1-14 ghrelin exhibitss characteristics of partial agonist for G 
protein and β-arrestin signaling activating G-proteins involved in ERK1/2 and 
GH release but with lower effect on G-proteins implicated in Akt signalling, 
i.e. Gi/o-protein. Differences in the pattern and dynamic of endocytosis may 
be related to the phosphorylation rate, although this pattern was adequate 
to induced Akt-associated adipogenic effect by β-arrestin signaling. Curiously, 
these results reveal the existence of specificity associated to scaffold protein 
complex. This would be the case for β-arrestin scaffolded ERK1/2 and Akt 
complexes, which appears to be regulated or determined by different 
mechanisms of assembly.  
 Regarding the peptide encompassing only the first 18 residues of 
ghrelin, COOH-GSS-(n-octanoyl)-FLSPEHQRVQQRKES-NH2 (1-18 ghrelin), 
GHSR1a phosphsorylation showed to be higher than in the case of 1-14 
ghrelin leading to a dynamic of endocytosis closer to the ghrelin-induced 
internalization. In this particular case, the activation pattern of ERK1/2 
showed the early peak phase associated to G-protein signaling. According to 
this pattern of ERK1/2 activation, the mitogenic effect was not observed. By 
contrast, the early peak and sustained phases of Akt activation 
corresponding to G-protein and β-arrestin signaling were activated. In fact, 
adipogenic action was similar to that obtained for ghrelin. GH release 
showed comparable levels to ghrelin. In this particular case, the absent of β-
arrestin-dependent ERK1/2 activation explains the lack of effect on 
mitogénesis similar to 1-14 ghrelin. A complete activation of Akt, i.e. G-
protein and β-arrestin signaling, correlates with the adipogenic effect, an 
effect not observed for 1-14 ghrelin. These results support the postulated 
specificity associated to scaffold protein complex. Although the receptor 
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endocytosis activated by 1-18 ghrelin was closer to that activated by ghrelin, 
this was not adequate to activate β-arrestin-dependent ERK1/2 signaling 
and, consequently, mitogenic functionality. 
 In conclusion, these evidences strongly support the idea of multiple 
active conformations in GHSR1a stabilized as a function of chemical structure 
of ligands or their pharmacological profiles. Another interesting idea is based 
on the architecture of ligand binding pockets in the GHSR1a and its 
association with the multiple active conformations and signaling. However, 
this hypothesis remains to be tested with rigorous experimentation, for 
example, by using receptor systems for which well-defined biased ligands 
and biased receptor mutants are available. Detailed mapping of 
conformational differences between receptors occupied with agonists 
remains to be carried out. Such information will be critical both for 
understanding the mechanism of agonisms at GHSR1a and for aiding in the 





































CHAPTER 1. GHSR1a phosphorylation. 
1. Mass spectrometry-based proteomic approach allow the mapping of 
five phosphorylation sites on the C-tail of the GHSR1a that can be 
divided into 2 different areas. Region 1 comprises T350 and S349, 
while region 2 emcompass S362, S363 and T366. Both regions appear to 
contribute equally to the overall phosphorylation of the receptor. 
2. The region 2 was primarily responsible for β-arrestin 1 and 2 
binding, receptor internalization, β-arrestin-mediated ERK1/2 and 
Akt activation. By contrast, region 1 appeared to play a subtler role 
of stabilizing the interaction between the receptor and β-arrestins. 
3. Our data are consistent with a model in which different 
phosphorylation pattern (barcode) on the GHSR1a can induce 
distinct interactions with β-arrestins that determine the ultimate 
cellular consequences of β-arrestins signaling. 
 
CHAPTER 2. PKCs and GRKs: role in GHSR1a signalling. 
1. Ghrelin-mediated GHSR1a phosphorylation is dependent on the 
activation of GRK2 and GRK6. In particular, GRK2 phosphorylates 
region 2, S362, S363 and T366, at the C-tail of GHSR1a. 
2. In the system ghrelin/GHSR1a GRK2 is activated by Gq/11-protein 
dependent PKCα pathway. 
3. GHSR1a phosphorylation mediated by GRK2 is proposed as a key 
event to activate β-arrestin-signaling, and consequently as a crucial 




CHAPTER 3. Determination of active conformations of GHSR1a. 
1. Data obtained from structural features of ghrelin supports the idea 
of multiple active conformations of GHSR1a which are stabilized as a 
function of the chemical structure of ligands. Such information will 
be critical for understanding the mechanism of agonisms at GHSR1a 
and for aiding in the design of pharmacological tools to selectively 






















 A ghrelina é una hormona peptídica de 28 aminoácidos, secretada 
en maior parte polo estómago e en menor proporción polo intestino, o 
páncreas, o ril, a placenta, o hipotálamo e a hipófise. Tratase do primeiro 
péptido natural acilado, debido o grupo n-octanoil que posúe na S3, e que 
ademais é esencial para a súa bioactividade, xa que lle permite traspasar a 
barreira hematoencefálica e unirse o seu receptor específico, o receptor de 
secretagogos da hormona do crecemento (GHSR1a). O GHSR1a expresase en 
diversas áreas do cerebro que inclúen a hipófise, o hipocampo, o núcleo 
arcuato hipotalámico, a substantia nigra pars compacta, a área tegmental 
ventral e os núcleos do rafé. A activación do GHSR1a na hipófise estimula a 
secreción da hormona do crecemento (GH). Ademais, a unión da ghrelina ao 
seu receptor nos neuropeptidos Y do hipotálamo induce apetito e estimula a 
inxesta. Ditos comportamentos de alimentación e recompensas asociados a 
ghrelina son controlados pola área tegmental ventral e o hipocampo. A nivel 
periférico o GHSR1a expresase nos illotes pancreáticos, a glándula 
suprarrenal, a tiroide, o miocardio, e o tecido adiposo. Ata o momento foron 
descritas numerosas accións periféricas da ghrelina que incluen: a regulación 
do metabolismo da glucosa, a lipoxénese, a supresión da termoxénese na 
graxa parda, e a mellora das funcións cardiovasculares como a vasodilatación 
ou a contractilidade. 
 A acción da ghrelina na activación do GHSR1a determina as vías de 
sinalización intracelular alcanzadas e polo tanto as funcións fisiolóxicas 
asociadas. As cascadas de sinalización descritas de xeito tradicional para o 
GHSR1a estaban mediadas polas proteínas G, principalmente Gq/11 e Gi/o. Sen 
embargo, más recentemente demostrouse que as β-arrestinas actúan como 
soporte de gran variedade de proteínas de sinalización en cascadas 
independentes das proteínas G. Inicialmente describiuse a implicación das β-
arrestinas na desensibilización do GHSR1a través da regulación da 
endocitose. Sen embargo, na actualidade está ben establecido que as β-
arrestinas están tamén implicadas na transdución de sinal da proteína 
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quinasa activada por mitóxenos (ERK1/2) e Akt. A activación de ERK1/2 a 
través do GHSR1a prodúcese por ambas vías, a mediada por proteínas G e a 
dependente das β-arrestinas. Na cascada mediada por Gi/o están implicadas: 
a proteína fosfatidilinositol 3-quinasa (PI3K), a proteína quinasa C ε, e a 
proteína non-receptor con actividade tirosina quinasa, cSrc. Nunha segunda 
vía de activación de ERK1/2 dependente de Gq/11 vense envoltas a proteína 
quinasa C α/β e cSrc. Por último, existe unha terceira ruta que implica o 
recrutamento do GHSR1a con cSrc, Raf 1, e ERK1/2 nun complexo no que as 
β-arrestinas actúan como soporte. Por outro lado, o GHSR1a tamén é capaz 
de activar Akt a través da interacción de distintos mecanismos de sinalización 
que implican unha activación tempera dependente de Gi/o e una tardía 
mediada polas β-arrestinas. Na primeira fase, activase a proteína PI3K a 
través de Gi/o e AKt translocase a membrana onde é fosforilada por cSrc en 
Tyrosina provocando que a piruvato deshidroxenasa kinasa1 (PDK1) fosforile 
a sua T308 e a diana de rapamicina en células de mamífero2 (mTORC2) a 
S473 situadas no loop A e no motivo hidrófobo de Akt respectivamente. Tras 
a activación do receptor, iniciase unha segunda vía de sinalización mediada 
polas β-arrestinas 1 e 2, que implica o recrutamento de cSrc e Akt. O 
complexo que se forma coas β-arrestinas como soporte conduce a activación 
completa de Akt a través de PDK1 e mTORC2, que no están asociados 
fisicamente o complexo. En ambas vías, cSrc fosforila a Y536 C-terminal da 
tyrosina fosfatasa SHP1 que exerce un efecto inhibidor sobre PI3K e Akt, o 
que converte a cSrc nun interruptor para controlar tanto la ruta dependente 
de Gi/o como a mediada polas β-arrestinas. Por outro lado, o noso grupo 
tamén demostrou que as β-arrestinas median as funcións adipoxénicas do 
sistema ghrelina/GHSR1a mediante a vinculación do receptor activado con 
distintos conxuntos de proteínas accesorias e efectoras, controlando deste 
xeito a especificidade, a eficiencia e maila capacidade das sinais. A nivel 
molecular, a inhibición das β-arrestinas durante a adipoxénese inducida por 
ghrelina diminuiu os niveis de C/EBPα, C/EBPδ, C/EBPβ, así como os niveis de 
PPARγ, provocando una redución significativa na acumulación de lípidos e o 
Resumo 175 
 
deterioro da diferenciación terminal de adipocitos. Este efecto, combinado 
coa inhibición significativa da activación de Akt inducida por ghrelina, 
corrobora que as β-arrestinas son clave na  transdución de sinal do sistema 
ghrelina/GHSR1a. Queda cada vez mais patente que as β-arrestinas, 
orixinalmente descubertas como meras proteínas adaptadoras necesarias 
para la endocitose do GHSR1a, teñen un papel moito más amplo no 
mantemento da homeostase celular. 
 A pesares de que a importancia do sistema ghrelina/GHSR1a é 
amplamente recoñecida, aínda non está claro cómo este receptor acoplado a 
proteínas G (GPCR) controla as súas diversas funcionalidades. No caso de 
outros GPCRS demostrouse que a fosforilación do receptor establece un 
código de barras que determina a interacción coas β-arrestinas e polo tanto, 
a actividade do mesmo. Tamén se viu que este código de barras fosforilación 
pode ser específico do tecido no que se estea a expresar o receptor, 
probablemente, porque cada tecido presenta un nivel distinto de expresión 
de proteínas quinasas, como as proteína quinasa de GPCR (GRKs) ou as  
proteínas quinasa C (PKC). 
 Por todo o exposto anteriormente, o noso traballo comezou 
realizando un estudo sobre o patrón de fosforilación do receptor GHSR1a 
como elemento determinante da súa actividade. Para levalo a termo, 
empregamos diferentes aproximacións co fin de elucidar os sitios precisos de 
fosforilación do GHSR1a tras a súa estimulación con ghrelina. Mediante a 
xeración de fosfopéptidos trípticos e a análise destes péptidos por 
cromatografía líquida acoplada a espectrometría de masas en tándem (LC-
MS/MS) determinamos que a ghrelina induce a fosforilacion do GHSR1a 
principalmente nos residuos S349, S362, S363 T350 and T366 que están situados  
todos eles na cola carboxilo terminal do receptor. A continuación, mediante 
mutaxénese dirixida dos sitios de fosforilación atopados xeráronse diversos 
mutantes do receptor marcados coa proteína verde fluorescente (EGFP) que 
sendo expresados nun sistema in vitro permitíronnos determinar a 
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implicación destes aminoácidos na sinalización derivada da activación do 
GHSR1a. Mentres os residuos mais terminais do receptor (S362, S363 and T366) 
demostraron promover a interacción das β-arrestinas co GHSR1a, a 
internalización do receptor así como a proliferación e a adipoxénese 
mediada por as β-arrestinas; os fosfo aceptores da zona más distal da cola 
(T350 and S349), mostráronse necesarios para estabilizar a interacción das β-
arrestinas co GHSR1a e polo tanto, como os  responsables finais da 
sinalización asociada as β-arrestinas. Sen embargo, a sinalización e 
funcionalidades asociadas o GHSR1a vía Gq/11 non se viron afectadas polo 
patrón de fosforilación do mesmo, o que nos leva a pensar que o receptor 
podería empregar ambas rutas dun xeito independente o que lle permitiría 
modular a súa actividade e funcionalidade. Finalmente, os resultados 
derivados desta parte do estudio demostran que os mecanismos de 
activación da ghrelina asociados a un patrón de fosforilación do receptor 
GHSR1a son determinantes das acciones biolóxicas de esta hormona. 
 Una vez elucidado o patrón de fosforilación do GHSR1a e a súa 
importancia na sinalización e funcionalidades asociadas o mesmo, 
procedemos a estudar os elementos implicados na indución de dita cascada 
intracelular asociada a fosforilación do receptor. Como xa mencionamos 
anteriormente, a especificidade do código de barras de fosforilación pode 
estar determinada pola expresión de quinasas como as GRK ou as PKC. O 
estudo do sistema ghrelina/GHSR1a en células HEK293 determinou que a 
ghrelina é capaz de inducir a activación de PKCs a través de Gi/o e Gq/11. Mais 
concretamente, a ruta Gi/o/PI3K/PKD1 regula a activación de PKCδ, PKCθ, 
PKCµ e PKCζ mentres PKCη e activada a través da vía mediada por Gq/11 e 
PKCα. Dito estudo confirmou ademais que a proteína quinasa D actúa como 
substrato de PKCs noveles (δ, ε, η y θ) e atípicas (ζ y ι / λ) a través da ruta 
dependente de Gi/o. Así mesmo, con este traballo conseguiuse establecer que 
a fosforilacion do GHSR1a é debida o papel das GRK2 e 6. De forma mais 
especifica, viuse que GRK2 é a encargada da fosforilacion dos residuos mais 
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terminais da cola do GHSR1a S362, S363 and T366 e polo tanto da unión do 
receptor coas β-arrestinas e a súa internalización. Finalmente, nesta parte do 
traballo logrouse conectar a vía das proteínas G coa fosforilación do 
receptor. Esta conexión viría dada polo feito de que GRK2 é por lavia 
mediada por Gq/11 e PKCα. O complexo sistema descrito determinaría a 
funcionalidade do receptor asociada o tecido diana de expresión. 
 Por último, neste traballo incluímos un estudo con diferentes 
truncados da ghrelina co fin de determinar os elementos estruturais 
determinantes da súa bioactividade. Créese que ademais da diferenza de 
expresión de GRKs y PKCs, o uso de distintos ligandos podería levar a 
prevalenza dunha vía de sinalización sobre outra ou a un distinto grao de 
activación da mesma, o cal nos permitiría seleccionar unha funcionalidade 
determinada do mesmo receptor. Do mesmo xeito, é importante a 
determinación da estrutura dos ligandos dun receptor xa que unha parte 
concreta dos mesmos podería activar unha conformación determinada do 
receptor e polo tanto inducir de forma especifica unha vía de sinalización. 
Con este estudo vimos que os cinco primeiros aminoácidos N-terminais da 
ghrelina son capaces de estimular a fosforilación e a sinalización mediada 
polo GHSR1a así como a súa actividade proliferativa e adipoxénica en niveis 
similares a os producidos pola ghrelina pero non son capaces de inducir 
secreción de GH. Por outro lado, os truncados que inclúen os 14 e os 18 
primeiros aminoacidos da ghrelina non foron quen de inducir un nivel de 
fosforilación comparable o da mesma. Ademais amosaron unha perda da 
sinalización mediada por β-arrestinas que conduciu a indución dunha menor 
actividade mitoxénica. Sen embargo, estes truncados si tiveron un efecto 
similar o da ghrelina na acumulación de lípidos e na secreción de GH. Todo 
isto, lévanos a pensar que a estrutura química dos ligandos exerce un papel 
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